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CHAPTER 1- INTRODUCTION: 
 
1.1 ATR and the DNA Damage Response 
 
 The DNA damage response (DDR) works together with DNA repair proteins in order to 
protect the cell from endogenous or environmental DNA-damaging agents or replication stress 
(1). Replication stress can come in the form of chemical modifications to nucleosides or DNA 
bases, aberrant DNA secondary structures, aberrant DNA binding proteins along the path of 
replication, low dexoynucleoside triphosphate (dNTP) pools, or collisions between the 
transcription and replication machineries (2,3). The main functions of the DDR are to arrest the 
cell cycle, recruit DNA repair proteins, and to initiate apoptosis if the damage is severe (4). 
Genes involved in the DDR are typically tumor suppressors because they prevent mutations in 
critical proto-oncogenes or tumor suppressors that could lead to cellular transformation (5). 
However, transformed cells can become reliant on DDR pathways in order to avoid apoptosis, so 
DDR genes can also be thought of as oncogenes and therefore potential targets for cancer 
therapy (6). Depending on the stage of the cell cycle and what type of damage is involved, 
different DDR pathways can be activated.   
 The main pathway that deals with DNA damage detected specifically in the S or G2 
phases of the cell cycle involves the ataxia telangiectasia mutated and Rad3-related (ATR) 
protein kinase (7,8). ATR is in the phosphatidylinositol 3-kinase-related kinase (PIKK) family 
and works to stabilize replication forks in response to DNA damage or replication stress (9,10). 
In response to replication stress or nucleotide excision repair intermediates, single-strand DNA 
(ssDNA) is formed. In addition to these scenarios, DNA double strand breaks (DSBs) can be 
resected to form ssDNA tails with 3’ ends, or depletion of dNTPs can result in ssDNA around 
replication forks (11). Next, ssDNA is coated with replication protein A (RPA), which interacts 
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with ATR-interacting protein (ATRIP) and activates ATR (12). ATR activation also requires 
localization of the heterotrimeric ring shaped 9-1-1 complex (made up of RAD9, RAD1, and 
HUS1) to the damaged site. This localization is accomplished through the interaction of RPA 
with RAD17. The 9-1-1 complex then recruits topoisomerase binding protein-1 (TOPBP1), 
which is crucial for ATR activation (13,14). Claspin brings ATR and checkpoint kinase 1 
(CHK1) into close proximity, and ATR then catalyzes phosphorylation of CHK1 (15). CHK1 
catalyzes phosphorylation of a host of proteins, including WEE1, CDC25A, and CDC25C to 
arrest the cell cycle. These phosphorylation events serve to inhibit cyclin-dependent kinase 
(CDK) activity. Inhibition of CDK1 results in G2/M arrest and inhibition of CDK2 results in S 
phase arrest (11). The ATR pathway also regulates activity and recruitment of DNA repair 
proteins. An early target of ATR signaling is histone H2AX; ATR catalyzes its phosphorylation 
to form γ-H2AX (16,17). γ-H2AX can then recruit DNA repair proteins and potentiates the DDR 
signal (18,19). ATR catalyzes phosphorylation of Fanconi-anemia proteins to promote 
localization to sites of cross-linked DNA damage (20). ATR can also recruit nucleotide excision 
repair proteins to DNA lesions by phosphorylating XPA (21). ATR activates BRCA1 through 
phosphorylation, thereby activating homologous recombination repair (HRR), which is a key 
DNA DSB repair mechanism. CHK1 phosphorylates and recruits RAD51 and BRCA2, which 
are also involved in HRR (11) (see Figure 1.1).  
 ATR is an essential gene in mice, displayed by the fact that an ATR null environment 
causes early embryonic lethality. These cells endure massive spontaneous chromosomal 
fragmentation, leading to cell death (22). Mouse cells with hypomorphic ATR accumulate DNA 
damage during S phase, and these mice experience an increased tumor incidence and early aging 
(22,23). Mutations causing hypomorphic ATR in humans are associated with Seckel syndrome,  
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Figure 1.1 Visual representation of the canonical ATR/Mec1 signaling pathway. See text for 
details. This figure was adapted from (24). 
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exemplified by severe developmental defects including microcephaly, severe growth retardation, 
and intellectual disability (25,26). This indicates the essential role of ATR in early development. 
Partial loss of ATR function also makes cells more susceptible to DNA-damaging agents. 
Overexpression of a catalytically inactive ATR mutant causes hypersensitivity to DNA-
damaging agents (7). ATR inhibition by caffeine causes radiosensitivity (27). ATR is also 
involved in recruitment of proteins associated with the replication fork after replication stress is 
induced (28). ATR inhibits transcription around stalled replication forks after treatment with 
doxorubicin (29). This illustrates the diverse functions of ATR in protecting genomic integrity in 
response to different types of stressors. 
 Although ATR is typically thought of as a tumor suppressor since it maintains genomic 
integrity (5,30), it can also facilitate carcinogenesis by preventing apoptosis in transformed cells. 
Cancer cells typically show elevated rates of replication stress, and the ATR pathway is critical 
in preventing excess DNA damage resulting from replication stress, which could lead to 
apoptosis or inviability (31,32). In a similar fashion, ATR is involved in the response to DNA-
damaging chemotherapy agents in cancer cells and could function as a method of resistance to 
cancer chemotherapy drugs (33-35). Other DDR pathways, which include the p53 and ATM 
tumor suppressors, are often mutated and/or inactivated in cancer cells (31,36). This creates a 
situation where cancer cells are dependent on the DDR pathway involving ATR in order to 
handle replication stress and DNA damage and thereby avoid apoptosis (37). These findings 
have led to the development of ATR inhibitors as a targeted therapy for cancer treatment. Several 
ATR inhibitors are currently being tested in clinical trials as a monotherapy or in combination 
with radiotherapy or DNA-damaging chemotherapy drugs such as carboplatin (37,38). The 
combination approach is related to synthetic lethality. If the DDR is inhibited while DNA 
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damage is being induced, then cancer cells should have no method of repairing DNA and will 
succumb to cell death.  
1.2 MEC1: The Yeast Ortholog of ATR 
 
S. cerevisiae Mitosis Entry Checkpoint 1 (Mec1) is structurally similar to human ATR 
and serves the same functional role (12,39). MEC1 is an essential gene (40); however, deletion of 
Suppressor of MEC1 Lethality 1 (SML1) can circumvent the lethality induced by deletion of 
MEC1. This occurs because during an unperturbed cell cycle the essential role of MEC1 is to 
regulate dNTP levels, and SML1 is a negative regulator of dNTP levels (41). Deletion of MEC1 
causes ssDNA bound by RPA to build up at replication forks and ultimately leads to DSB 
formation (42). In response to DNA damage or replication stress, Mec1 activates the Dun1 
kinase, which inhibits Sml1 activity and thereby increases dNTP pools (43). Mutations in MEC1 
cause cells to be hypersensitive to DNA-damaging agents (44-46). In response to replication 
stress, mec1 mutants lose control over replication initiation, which leads to an inability to restart 
replication fork progression. The cells then prematurely enter mitosis, which ultimately causes 
loss of viability (47). This indicates the differential functions of MEC1 in response to stress 
versus during normal cell cycle progression.  
Rad53 is a major target of Mec1 signaling in yeast and plays a similar functional role as 
human CHK1; (48) however, the human structural ortholog of Rad53 is CHK2 (49). Mec1 
catalyzes phosphorylation of Rad53, which is dependent on the Rad9 mediator protein (50). 
Rad53 then autophosphorylates, which increases kinase activity by 9-fold (51). Like CHK1, 
Rad53 then goes on to catalyze phosphorylation of a number of substrates to induce cell cycle 
arrest, upregulate DNA repair proteins expression, and stabilize replication forks (52-55). 
Another key target of Mec1 is H2A. Analogous to human ATR catalyzing phosphorylation of γ-
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H2AX, Mec1 catalyzes phosphorylation of H2A to generate γ-H2A, which promotes DSB repair 
(56,57) (see Figure 1.1). 
The Mec1 pathway is also intimately involved in regulation of transcription. Chromatin 
restructuring from the generation of γ-H2A could be a mechanism that inhibits transcription in 
response to stressors in yeast. In response to replication stress, proteins involved in regulating 
transcription were found to be phosphorylation substrates of Mec1 and a related PIKK, Tel1, the 
ortholog of human ATM (58). Mec1 senses nutrient deprivation and can downregulate Snf1 in 
order to lead the cell away from respiration toward fermentation, analogous to the Warburg 
effect in cancer cells (59). Mec1 also functions in preventing conflicts between the replication 
and transcription machineries, which can be caused by stalled replication forks (60). 
Hydroxyurea (HU) treatment causes replication fork stalling by depleting nucleotide pools and 
also induces gene transcription, which causes conflicts between the two machineries and 
eventually chromosome breakage (61). Mec1 functions in resolving stalled replication forks, as 
stated earlier, and Mec1 also evicts transcription machineries. When replication and transcription 
are conflicting, Mec1 plays a role in removing RNA Polymerase II from DNA to preserve 
replication fork integrity (62). Mec1 also functions in detaching transcribed genes from the 
nuclear pore complex to protect replication forks in replication-transcription conflicts (63).   
1.3 DBF4 in the DDR and DNA Replication 
 
A key downstream target of the DDR is the replication machinery, which is inhibited in 
order to prevent replication fork stalling upon collision with DNA damage. ATR catalyzes 
phosphorylation of MCM2, a component of the MCM2-7 helicase complex that initiates DNA 
replication (64,65). Two other key downstream components of the Mec1 pathway that regulate 
origin firing are Sld3 (66) and Dbf4 (67-69). Sld3 is an essential protein that associates with 
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Cdc45 and functions in unwinding origins and initiation of DNA replication (70). Dbf4 is the 
regulatory subunit of the Cdc7 kinase that catalyzes phosphorylation of the MCM2-7 helicase 
complex to assist in initiation of DNA replication (71-73). Together, Dbf4 and Cdc7 make up 
Dbf4-dependent kinase (DDK). Sld3 and Dbf4 phosphorylation is important for preventing late 
origin firing in response to replication stress or DNA damage (66,68). Dbf4 physically interacts 
with Rad53 (74-77) and is required to sustain the hyperphosphorylated state of Rad53 (78).  
 Dbf4 function has been studied extensively in S. cerevisiae. DDK is involved in meiotic 
progression (79), replication checkpoint activation (78), translesion synthesis (80), histone 
regulation (81), and exit from mitosis (82). Cdc7 levels stay constant throughout the cell cycle, 
but Cdc7 is catalytically inactive until bound to Dbf4 (83,84). In contrast, Dbf4 expression is 
highest in late G1 and S phases of the cell cycle, and Dbf4 is degraded after mitosis is complete 
(83,85-88). Since Dbf4 is required to be in complex with Cdc7 in order for it to be catalytically 
active, Dbf4 expression regulates Cdc7 activity throughout the cell cycle. Phosphorylation of 
Dbf4 inhibits its activity, thereby inhibiting MCM phosphorylation and origin firing. In this way, 
Dbf4 is a key downstream target of the DDR to inhibit DNA replication when the cell cycle has 
been arrested (89).  
Proteins involved in the DBF4 and ATR pathways directly and indirectly interact in 
several ways. In response to replication fork stalling, Rad53 catalyzes phosphorylation of Dbf4, 
which prevents late origin firing (66,68,88,90). In human cells, the mediator of ATR 
phosphorylation of CHK1, Claspin, interacts directly with Cdc7. Claspin can recruit Cdc7 to 
DNA for efficient phosphorylation of the MCM complex (91). CDC7 also catalyzes 
phosphorylation of Claspin in the replication checkpoint (92,93). ATR has been shown to 
directly catalyze phosphorylation of DBF4 and inhibit DNA replication. However, CDC7 
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catalytic function was not compromised by phosphorylation of DBF4 by ATR. This 
phosphorylation was also shown to be important for preventing DNA rereplication (94).  
The overarching theme for these studies is to examine the functional roles of ATR/MEC1 
in response to different stressors such as gene deletion or DNA rereplication. One aim of these 
studies is described in Chapter 2, which demonstrates the functions of MEC1 and DBF4 in 
preventing DNA rereplication during meiosis. ATR is important during meiotic checkpoints, so 
these studies could provide a greater understanding of how meiotic mechanisms can become 
defective and possible causes of infertility or genetic disorders. The other aim is described in 
Chapter 3, which investigates how ATR/MEC1 and DBF4 or other genes functionally interact 
during the normal cell cycle and how this pertains to cancer therapy. ATR activation is a 
significant adaptive mechanism in cancer cells, and these studies could give us additional targets 
to inhibit as cancer therapy along with inhibiting ATR. In addition, they could reveal genetic 
backgrounds that might make ATR inhibition a particularly effective therapy.  
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CHAPTER 2- THE ROLES OF MEC1 AND DBF4 IN PREVENTION OF DNA 
REREPLICATION IN THE MEIOTIC RECOMBINATION CHECKPOINT  
 
2.1 Introduction 
 
DNA replication occurs early during meiosis and is necessary for the subsequent 
formation of haploid gametes through two consecutive rounds of chromosome segregation. 
Meiotic DNA replication is tightly regulated so that initiation occurs exactly once and at the 
correct time during meiosis (95). Without checkpoint systems, errors such as DNA rereplication 
can occur that can cause genome instability and gene amplification (96). CDK complexes are 
central regulators of eukaryotic DNA replication initiation, both in the mitotic cell cycle (97) 
and in meiosis (98-100). Our lab has previously discovered that meiotic expression of a 
stabilized form of the B-type cyclin-CDK inhibitor Sic1 leads to DNA rereplication in 
Saccharomyces cerevisiae (101). This is consistent with CDK preventing DNA rereplication 
during the mitotic cell cycle by inhibiting the reformation of the pre-replicative complex 
(97,102,103). 
Meiotic DNA replication is followed by programmed recombination between 
homologous chromosomes during prophase I in S. cerevisiae as well as most eukaryotes. 
Recombination allows for the physical interaction of homologs, which is important for accurate 
chromosome segregation during this division. Recombination also functions in transferring 
genetic information between the parental chromosomes as a means of increased genetic 
diversity. Spo11 creates a DSB that can then initiate the process of recombination (104,105), and 
there are controls to ensure that each chromosome completes at least one recombination event 
(106). Each DSB is processed to generate 3’-ssDNA overhangs that invade the homologous 
duplex chromosome; this process is termed strand invasion (107,108). Without the meiosis-
specific DNA recombinase Dmc1, strand invasion cannot proceed and extensive DNA resection 
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results. DNA resection forms ssDNA and recombination intermediates that activate the meiotic 
recombination checkpoint response that then prevents meiotic progression past prophase I 
(109,110).  
The meiotic recombination checkpoint pathway that is activated by deletion of DMC1 
(dmc1Δ) is similar to DNA damage checkpoint pathways that function during the mitotic cell 
cycle (111). Mec1 and its associated protein Ddc2, the ortholog of human ATR-interacting 
protein (ATRIP), function in both pathways. A facilitator of Mec1 function, the Ddc1-Mec3-
Rad17 (“9-1-1”) complex, is also involved in both meiotic and mitotic checkpoint pathways 
(24,111-116). The Dot1 methyltransferase is similarly involved in both pathways (117-119). 
Rad53 and its mediator Rad9 (53,113,120-122) have not been found to be involved in the 
meiotic recombination checkpoint (109,111,123). However, Rad53 and Rad9 are involved in 
meiotic checkpoints in certain circumstances, including the response to HU, which depletes 
nucleotide pools (124) and to DNA damage not induced by Spo11 (125,126). In the meiotic 
recombination checkpoint, meiosis-specific proteins respond to recombination intermediate 
structures and perform similar functions to Rad53 and Rad9 (110,123,127). These include Hop1, 
Red1, and Mek1, components of the sister chromatid derived axial elements that are important 
for proper meiotic recombination. Hop1 and Red1 are structural proteins (128,129), while Mek1 
is a protein kinase similar in sequence to Rad53 (123,130,131). These proteins help to enforce 
inter-homolog recombination during unperturbed meiosis and prevent inter-sister recombination, 
thereby promoting normal chromosome segregation (130,132-136). Deletion of DMC1 activates 
the meiotic recombination checkpoint where Red1 associates with the 9-1-1 complex and 
facilitates Mec1 activation (137). Mec1 then phosphorylates Hop1, which is required for Mek1 
activation (138). Active Mek1 prevents excessive recombination between sister chromatids and 
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thereby maintains the checkpoint signal (139,140). Mek1 also halts meiotic progression in cells 
displaying defective DSB repair (110,126,133).  
The Brush lab has developed a system in which cells induced to undergo meiosis 
(sporulation) experience DNA rereplication (101). This phenotype occurs when CDK activity is 
deregulated through early meiosis-specific expression (via the HOP1 promoter) of SIC1∆PHA, an 
HA-tagged Sic1 variant that lacks critical CDK phosphorylation sites necessary for Sic1 
degradation (141). DNA rereplication does not occur in this system when the Sic1HA 
phosphorylation sites are not altered, because HA-tagged Sic1 is subject to phosphorylation and 
degradation, like normal Sic1. It was further found that deletion of DMC1 (dmc1Δ) activates a 
response that prevents the DNA rereplication phenotype normally observed in the SIC1∆PHA 
cells. This pathway was examined genetically by further mutating genes in the SIC1∆PHA dmc1∆ 
strain. If there was a return to the rereplication phenotype after gene mutation in the SIC1∆PHA 
dmc1∆ background, it infers that the gene is necessary to prevent DNA rereplication after the 
meiotic recombination checkpoint has been activated by the absence of DMC1.  
2.2 Materials and Methods 
 
2.2.1 Strains 
 
Yeast strains used in this study are listed in Table 2.1. Generation of the HOP1pr-
SIC1∆PHA strain was described previously (101). Most deletion mutant diploids were first 
generated in haploids by homology-directed site-specific replacement with selectable markers 
(142). PCR-amplification was performed from either a plasmid (143) or genomic DNA of a 
mutant from the deletion set to generate the markers (144) (GE Dharmacon). Other mutants used 
to create our diploid mutants in the W303 background were kindly provided by the following  
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Table 2.1. Yeast strains. 
Strain Relevant Genotype Designation 
YGB495 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 SIC1∆PHA a 
YGB535 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 
dmc1∆::kanMX4/” 
SIC1∆PHA dmc1∆ a,b 
YGB604 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” SIC1∆PHA dmc1∆ a 
YGB679 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”   
mek1∆::kanMX4/” 
SIC1∆PHA dmc1∆ 
mek1∆ 
YGB758 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 
rad9∆::kanMX4/” 
SIC1∆PHA rad9∆ 
YGB759 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3  
dmc1∆::natR/”rad9∆::kanMX4/”  
SIC1∆PHA dmc1∆ 
rad9∆ 
YGB788 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 
mec1∆::LEU2/” sml1∆::kanMX4/” 
SIC1∆PHA mec1∆ 
sml1∆ 
YGB789 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3  
dmc1∆::natR/” mec1∆::LEU2/” sml1∆::kanMX4/”  
SIC1∆PHA dmc1∆ 
mec1∆ sml1∆ 
YGB866 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 mcm5-
bob1::HIS3/” sld3-38A-10his-13myc::kanMX/”  
SIC1∆PHA mcm5-
bob1 sld3-38A 
YGB867 
 
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”  
mcm5-bob1::HIS3/” sld3-38A-10his-13myc::kanMX/”  
SIC1∆PHA dmc1∆ 
mcm5-bob1 sld3-
38A 
YGB934 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” 
hta1-S129A::his3MX6/” hta2-S129A::TRP1/” 
SIC1∆PHA dmc1∆ 
h2a-S129A 
YGB938 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” 
mek1∆::kanMX4/” rad54∆::TRP1/rad54∆::HIS3 
SIC1∆PHA dmc1∆ 
mek1∆ rad54∆ 
YGB966 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” 
dot1∆::kanMX6/” 
SIC1∆PHA dmc1∆ 
dot1∆ 
YGB967 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” 
hta1-S129A::his3MX6/” hta2-S129A::TRP1/” 
dot1∆::kanMX6/” 
SIC1∆PHA dmc1∆ 
h2a-S129A dot1∆ 
YGB1012 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 
rad54∆::TRP1/rad54∆::HIS3 
SIC1∆PHA rad54∆ 
YGB1014 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 hta1-
S129A::his3MX6/” hta2-S129A::TRP1/” 
SIC1∆PHA h2a-
S129A 
YGB1075 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” 
dbf4∆::TRP1/” his3::PDBF4-dbf4-4A::HIS3/” sld3-38A-
10his-13myc::kanMX/” 
SIC1∆PHA dmc1∆ 
dbf4-4A sld3-38A 
YGB1241 
 
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/” 
sml1∆::kanMX4/” 
SIC1∆PHA dmc1∆ 
sml1∆ 
YGB1255 ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 
DMC1/dmc1∆::natR dbf4∆::TRP1/” his3::PDBF4-dbf4-
4A::HIS3/” sld3-38A-10his-13myc::kanMX/” 
SIC1∆PHA dbf4-4A 
sld3-38A 
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researchers: SKY2939 (h2a-S129A) (145) by Stephen Kron (University of Chicago), YFL234 
(dot1Δ) (118) by Marco Muzi-Falconi (Università degli Studi di Milano), and Y2359 and Y2573 
(dbf4-4A, sld3-38A, and mcm5-bob1) (68) by Philip Zegerman (The Gurdon Institute, UK) and 
John Diffley (The Francis Crick Institute, UK). Crossing was then used to establish these 
mutations into our mutant background. The mutations were added into MATa cells and MATα 
cells either containing the HOP1pr-SIC1∆PHA module already or added later, and then the two 
cell types were mated. The SIC1∆PHA designation signifies that there is a single copy of the 
HOP1pr-SIC1∆PHA element, but other designations signify that both copies have been altered. 
PCR was used to confirm the gene mutations in all cases. Point mutants such as the mutant sld3 
and dbf4 alleles were verified by DNA sequencing.  
2.2.2 Cell Culture  
 
For this project, yeast strains were incubated at 30°C. Induction of meiosis was carried 
out by a synchronous sporulation starvation procedure (146). Yeast cells were first streaked onto 
solid (2% (w/v) agar) YPG medium (1% (w/v) yeast extract, 2% (w/v) peptone, 3% (v/v) 
glycerol). In some cases, when colonies were growing slowly on YPG we instead streaked onto 
solid YPD medium (1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose). Plates were 
incubated for 3-4 days, and then liquid YPD was inoculated with single colonies. Cultures were 
incubated overnight then were used to inoculate liquid YPA (1% (w/v) yeast extract, 2% (w/v) 
peptone, 2% (w/v) potassium acetate) at an OD600 of 0.2 and incubated for 16 hours. Cultures 
were then normalized to the OD600 value of the strain with the lowest cell density and inoculated 
into sporulation medium (0.3% (w/v) potassium acetate and 0.02% (w/v) raffinose supplemented 
with leucine, arginine, and histidine each at 250 µM, tryptophan at 100 µM, and uracil at 50 µM). 
Sporulation media cultures were incubated for 24 hours and aliquots were harvested at indicated 
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time points for DNA content and protein analyses. All experiments included the SIC1∆PHA and 
SIC1∆PHA dmc1∆ strains as positive and negative controls, respectively. Each experiment was 
repeated independently at least three times.  
Strains grown in a mitotic cell cycle time course were used as controls in several 
experiments. Overnight cultures of MATa cells were brought to an OD600 of 0.2 and incubated 
for two hours. Cultures were arrested in G1 by incubating for two hours with yeast mating 
pheromone α-factor (Zymo Research) at a concentration of 2.5 µM in YPD. Then the media was 
removed and cells were washed with sterile water to dilute the α-factor. Fresh YPD was added to 
the cells and aliquots were taken every 15 minutes for DNA content and western blotting 
analyses. For hydroxyurea (HU) treated controls, cells were arrested with α-factor as described 
and released into 0.8X YPD with 0.2 M HU (MP Biomedicals).  
2.2.3 DNA Content 
 
 Flow cytometry was used to measure DNA content. Aliquots from time courses were 
immediately centrifuged, resuspended in 70% ethanol to fix the cells and then stored at 4°C. The 
fixed cells were washed with 1 ml 50 mM Tris–HCl, pH 7.5, resuspended in 1 ml of the same 
buffer, and 250 µg of RNase A was added. Samples were incubated at 37°C for 1 hour, and 250 
µg of proteinase K was subsequently added to the samples and incubated at the same conditions. 
Digested samples were incubated overnight at 4°C with 10X SYBR Green I (Molecular Probes). 
Samples were briefly sonicated before analyzing with a FACSCanto II flow cytometer (BD 
Biosciences) at the Microscopy, Imaging, and Cytometry Resources Core at Wayne State 
University School of Medicine. WinMDI freeware was used to create DNA content histograms.  
2.2.4 Protein  
 
Samples of cells from time courses were centrifuged, media was aspirated, and cell 
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pellets were stored at -70°C. For most experiments, an alkaline extraction method (147) was 
used to denature whole-cell extracts. For experiments analyzing Rad53, a tricholoroacetic acid 
bead beating method was performed (148). After protein extraction, samples were exposed to 
SDS-polyacrylamide electrophoresis. For western blotting, the resolved proteins were transferred 
to nitrocellulose (GE Healthcare). Primary antibodies included rat anti-α-tubulin (Serotec), 
mouse anti-hemagglutinin (Covance), rabbit anti-yeast γ-H2A (kindly provided by Christophe 
Redon and William Bonner, National Cancer Institute) (149), and rabbit anti-Rad53 (Abcam). 
Signals were generated with IRDye 800-conjugated goat anti-rat (Rockland), Alexa Fluor 680 
goat anti-rabbit (Invitrogen), or Alexa Fluor 680 goat anti-mouse (Invitrogen) secondary 
antibodies. The Odyssey infrared imaging system (Li-Cor) was used to visualize reactive bands. 
For the Rad53 autophosphorylation in situ assay, resolved proteins were transferred to PVDF 
(Millipore) and analyzed as described (148). 
2.3 Results 
 
2.3.1 Mec1 and Mek1 Prevent DNA Rereplication during the Meiotic Recombination 
Checkpoint 
 
The Brush laboratory previously showed that deletion of HOP1 or RED1 restored DNA 
rereplication in SIC1∆PHA dmc1Δ cells, indicating that they are each required for prevention of 
DNA rereplication in our system. In these cases, DNA rereplication was robust, exhibited by the 
generation of cells with DNA content reaching ~16C in some cases (150). Deletion of RAD17, 
which encodes a 9-1-1 member, also results in a return to the rereplication phenotype in the 
SIC1∆PHA dmc1Δ strain, indicating that RAD17 is required for suppression of DNA rereplication 
in our system (101). Since the 9-1-1 complex is a critical activator of the Mec1-mediated DDR, 
we hypothesized that Mec1 would also be involved in the meiotic recombination checkpoint. A 
mec1∆ sml1∆ mutant was generated in the SIC1∆PHA dmc1Δ background, and DNA rereplication 
16 
		
was observed in the SIC1∆PHA dmc1∆ mec1∆ sml1∆ cells. This phenotype was not due to sml1∆, 
because SIC1∆PHA dmc1∆ sml1∆ cells did not display DNA rereplication (Figure 2.1). 
Therefore, MEC1 is required for prevention of DNA rereplication in meiotic SIC1∆PHA dmc1∆ 
cells. Less robust DNA rereplication was observed in SIC1∆PHA dmc1∆ mec1∆ sml1∆ cells than 
in SIC1∆PHA cells. Some of this effect may have been due to the absence of MEC1 and SML1 
since SIC1∆PHA mec1∆ sml1∆ cells show slightly less rereplication than SIC1∆PHA cells (Figure 
2.2). SIC1∆PHA expression was also probed by using an antibody against HA, and SIC1∆PHA 
expression was found to be approximately equal between strains. SIC1∆PHA was expressed early 
during meiosis in the four-hour time point and was not degraded by the 24-hour time point. 
Therefore, differences in SIC1∆PHA expression cannot be the reason for the differences in DNA 
rereplication observed between strains (Figure 2.1). HA expression was probed after every time 
course, and the same pattern was seen in each experiment. 
A SIC1∆PHA dmc1∆ mek1∆ strain was then examined for DNA rereplication. Similar to 
deletion of MEC1, deletion of MEK1 also caused DNA rereplication in the SIC1∆PHA dmc1∆ 
background. RAD54 is involved in inter-sister repair during both meiosis and mitosis (151). It 
was shown that dmc1∆ mek1∆ cells that are also rad54∆ and therefore incapable of completing 
inter-sister repair progress through meiosis, but with slower dynamics (126,152). Therefore, 
Mek1 has separate roles in preventing inter-sister repair and in preventing meiotic progression. 
To determine whether the MEK1 function to suppress inter-sister repair or its function in 
preventing meiotic progression was the reason for the phenotype detected in our system, 
SIC1∆PHA dmc1∆ mek1∆ rad54∆ cells were examined. The rescue of DNA rereplication 
observed in SIC1∆PHA dmc1Δ mek1Δ cells was not identified after the addition of rad54∆ 
(Figure 2.3). An increase in phosphorylated histone H2A (γ-H2A), a marker for DSBs (153), was  
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Figure 2.1 MEC1 is essential for dmc1Δ-dependent prevention of SIC1∆PHA-induced DNA 
rereplication. Strains were induced to undergo meiosis by performing a synchronous sporulation 
protocol. Samples were taken for protein and DNA content at the indicated time points. Western 
blotting was then performed to examine HA (Sic1∆PHA) and tubulin. Flow cytometry was 
performed to observe DNA content. For all figures, 4C indicates diploid cells that have 
experienced one round of DNA replication. Cells that have undergone DNA rereplication are 
located to the right of the 4C peak.  
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Figure 2.2 MEC1 is required for robust DNA rereplication in the SIC1∆PHA background. 
Strains were induced to undergo meiosis by performing a synchronous sporulation protocol. 
Samples were taken for protein and DNA content at the indicated time points. Western blotting 
was then performed to examine HA (Sic1∆PHA) and tubulin. Flow cytometry was performed to 
observe DNA content. 
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Figure 2.3 MEK1 is essential for prevention of SIC1∆PHA-induced DNA rereplication when 
the meiotic recombination checkpoint is activated by deletion of DMC1. Strains were 
induced to undergo meiosis by performing a synchronous sporulation protocol. Samples were 
taken for protein and DNA content at the indicated time points. Western blotting was then 
performed to examine HA (Sic1∆PHA), γ-H2A, and tubulin. Flow cytometry was performed to 
observe DNA content. 
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observed in each strain. These data implied a persistence of DSBs throughout the meiotic time 
course regardless of DMC1 or RAD54 status. RAD54 itself was not required for the DNA 
rereplication phenotype (Figure 2.4). These data suggest that MEK1 inhibited DNA rereplication 
because of its function in preventing inter-sister repair and maintaining the DSB-induced signal 
rather than by halting DNA replication itself or halting meiotic progression.  
2.3.2 γ-H2A and Dot1 Prevent DNA Rereplication during the Meiotic Recombination 
Checkpoint   
 
Mec1 and Tel1 phosphorylate H2A at serine 129 (γ-H2A), which promotes DSB repair 
(56,57) and functions in the G1 DNA damage checkpoint (154,155). Since MEC1 was required 
to prevent DNA rereplication in our system, we hypothesized that one of its major targets may be 
as well. γ-H2A was generated in cells with wild type H2A (HTA1 and HTA2) regardless of 
DMC1 status (see Figure 2.3). A SIC1ΔPHA strain was generated with serine to alanine mutations 
in both HTA1 and HTA2 (h2a-S129A) so that the two H2A subunits could not be phosphorylated 
at this position. Western blotting confirmed that these cells did not express γ-H2A (Figure 2.4 
and Figure 2.5). Importantly, absence of γ-H2A led to DNA rereplication in SIC1∆PHA dmc1Δ 
cells. Again, the rereplication phenotype was not as extensive as in SIC1∆PHA cells with regard 
to total number of cells exhibiting >4C DNA or  >~8C, but the DNA rereplication was well-
defined and repeatedly observed (Figure 2.6). As a control, SIC1∆PHA h2a-S129A cells were also 
shown to rereplicate their DNA with some cells clearly displaying >~8C DNA content (Figure 
2.4). 
It was further hypothesized that another integral gene involved in the G1 DNA damage 
response, DOT1 (118,119), would be required for the meiotic response to DNA rereplication in 
our system. DOT1 encodes a histone methyltransferase that catalyzes methylation of histone H3 
at lysine K79 (156-158) and has been shown previously to be involved in the meiotic  
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Figure 2.4 Deletion of RAD54 or mutation of H2A does not affect the SIC1∆PHA-induced 
DNA rereplication phenotype. Strains were induced to undergo meiosis by performing a 
synchronous sporulation protocol. Samples were taken for protein and DNA content at the 
indicated time points. Western blotting was then performed to examine HA (Sic1∆PHA) and 
tubulin. Flow cytometry was performed to observe DNA content. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
		
 
 
Figure 2.5 SIC1ΔPHA dmc1Δ h2a-S129A cells do not express γ-H2A during the meiotic time 
course. Strains were induced to undergo meiosis by performing a synchronous sporulation 
protocol. Samples were taken for protein at the indicated time points. Western blotting was then 
performed to examine γ-H2A and tubulin.  
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Figure 2.6 γ-H2A and DOT1 are required for dmc1Δ-dependent inhibition of SIC1∆PHA-
induced DNA rereplication. Strains were induced to undergo meiosis by performing a 
synchronous sporulation protocol. Samples were taken for protein and DNA content at the 
indicated time points. Western blotting was then performed to examine HA (Sic1∆PHA) and 
tubulin. Flow cytometry was performed to observe DNA content. 
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recombination checkpoint response (117). In a similar manner as h2a-S129A, an intermediate 
amount of DNA rereplication was observed in SIC1∆PHA dmc1Δ dot1∆ cells. Interestingly, 
combination of the dot1∆ and h2a-S129A mutations in the SIC1∆PHA dmc1Δ background did not 
enhance the amount of DNA rereplication compared with either single mutant (Figure 2.6). 
These data suggest that γ-H2A and Dot1 operated in the same pathway to prevent DNA 
rereplication in SIC1∆PHA dmc1Δ cells. 
2.3.3 Dbf4 and Sld3 Phosphorylation is Required for Prevention of DNA Rereplication 
During the Meiotic Recombination Checkpoint  
 
Rad53 has not been shown to be involved in the meiotic recombination checkpoint, but it 
can be activated by genotoxic stress during meiosis (124-126). With Rad53 being a crucial 
downstream signaling kinase in the Mec1 pathway during the mitotic cell cycle (48) and Mec1 
being essential for the meiotic checkpoint response to DNA rereplication (Figure 2.1), we 
hypothesized that Rad53 would be involved in prevention of DNA rereplication as well. With 
these two pieces of conflicting evidence, it was elected to determine whether RAD53 was active 
in the meiotic checkpoint that prevents DNA rereplication in our system. Like MEC1, RAD53 is 
an essential gene, but rad53Δ cells are viable when SML1 is also defective (41). Surprisingly, 
SIC1∆PHA rad53∆ sml1-1 cells did not exhibit DNA rereplication (150). This makes it 
impossible to identify genetically whether RAD53 itself is required for the dmc1∆-induced 
meiotic checkpoint response in preventing DNA rereplication since RAD53 deletion prevents 
DNA rereplication in the SIC1∆PHA background.  
So we elected to examine RAD9, which encodes a mediator of Rad53 activation 
(121,159,160). Importantly, rad9∆ did not prevent DNA rereplication in the SIC1∆PHA 
background (150). SIC1∆PHA dmc1∆ rad9∆ cells did not exhibit DNA rereplication, indicating 
that RAD9 was not required for suppression of DNA rereplication in SIC1∆PHA dmc1Δ cells 
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(Figure 2.7). This infers that RAD9 was not required for this checkpoint response to DNA 
rereplication. Since the function of RAD53 could not be studied through gene deletion, genes that 
function downstream of Rad53 in the mitotic checkpoint response were studied to investigate 
whether they also function in the meiotic checkpoint response to DNA rereplication. Rad53 
responds to DNA damage or replication fork stalling during S phase of the mitotic cell cycle and 
is activated to catalyze phosphorylation of Dbf4 and Sld3, which prevents firing of late origins 
(66,68). Two different mutant strains were used to determine whether this process could be 
involved in the meiotic response to DNA rereplication in our system. One strain contains mutant 
alleles of both DBF4 and SLD3, with mutations in important phosphorylation targets of Rad53. 
SIC1∆PHA dmc1∆ cells containing the mutant dbf4-4A and sld3-38A alleles demonstrated DNA 
rereplication (Figure 2.8), indicating that phosphorylation of Dbf4 or Sld3, or both proteins, was 
required for full prevention of DNA rereplication. These cells appeared to rereplicate their DNA 
to a lesser extent than SIC1∆PHA cells in that they did not exhibit >~8C DNA content, as in the 
case of SIC1∆PHA dmc1∆ h2A-S129A cells. In SIC1∆PHA dbf4-4A sld3-38A cells, robust DNA 
rereplication was detected with some cells displaying >~8C DNA content, indicating that the 
phosphorylation site mutations themselves were not responsible for limiting DNA rereplication 
(Figure 2.9). The second mutant strain contains the sld3-38A allele together with mcm5-bob1, a 
mutant allele that bypasses the essential function of DBF4 (161). DNA rereplication was not 
recovered after addition of mcm5-bob1 sld3-38A alleles into SIC1∆PHA dmc1∆ cells (Figure 2.8). 
As a control, it was confirmed that the mcm5-bob1 allele alone did not prevent DNA 
rereplication in the SIC1∆PHA background (150). Previous mitotic cell cycle results indicated that 
cells with mutated Dbf4 phosphorylation sites behaved similarly to cells with the mcm5-bob1 
allele. Our results displayed a clear difference between the two strains, but certain experimental  
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Figure 2.7 Rad53 is not activated during the dmc1∆-dependent meiotic recombination 
checkpoint. A, Strains were induced to undergo meiosis by performing a synchronous 
sporulation protocol. Samples were taken for protein and DNA content at the indicated time 
points. Western blotting was then performed to examine HA (Sic1∆PHA) and tubulin. Flow 
cytometry was performed to observe DNA content. B, Western blotting for Rad53 (top panel) 
and Rad53 autophosphorylation in situ (32P-Rad53, middle panel) were performed using the 
same samples from the synchronous sporulation experiment shown in A. Ponceau S staining 
(bottom panel) was used to determine total protein loading. Vegetative SIC1ΔPHA dmc1Δ 
(RAD53) and rad53Δ sml1-1 (rad53Δ) diploids were treated with HU for the indicated times as 
positive and negative controls, respectively. 
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Figure 2.8 Phosphorylation sites on Sld3 and/or Dbf4 that are normally targeted by Rad53 
are required for suppression of DNA rereplication. Strains were induced to undergo meiosis 
by performing a synchronous sporulation protocol. Samples were taken for protein and DNA 
content at the indicated time points. Western blotting was then performed to examine HA 
(Sic1∆PHA) and tubulin. Flow cytometry was performed to observe DNA content. 
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Figure 2.9 Mutations in DBF4 and SLD3 phosphorylation sites or mutations in MCM5 and 
SLD3 do not block DNA rereplication induced by SIC1∆PHA. Strains were induced to 
undergo meiosis by performing a synchronous sporulation protocol. Samples were taken for 
protein and DNA content at the indicated time points. Western blotting was then performed to 
examine HA (Sic1∆PHA) and tubulin. Flow cytometry was performed to observe DNA content. 
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factors may cause the difference seen between our meiotic studies and previous mitotic cell cycle 
studies (see Discussion). These data imply that Dbf4 phosphorylation was sufficient in order to 
prevent DNA rereplication, at least with the addition of the mcm5-bob1 allele. Notably, either 
Dbf4 or Sld3 phosphorylation alone can help to prevent late origin firing in mitotic S phase 
(66,68). In conclusion, Rad53 phosphorylation targets in the mitotic cell cycle also functioned to 
prevent meiotic DNA rereplication in our system. These seemingly incongruent results show that 
a mediator of Rad53 activity, Rad9 is not necessary for prevention of DNA rereplication, yet 
Dbf4 and/or Sld3 phosphorylation sites that are normally targeted by Rad53 are required for 
prevention of DNA rereplication in our system. The RAD9 data shows that Rad53 is probably not 
involved, however the Dbf4 and Sld3 phosphorylation site data indicates that Rad53 may be 
involved in prevention of DNA rereplication in our system. Therefore, Rad53 enzymatic activity 
during meiosis was directly probed in our system.  
2.3.4 Rad53 is not Activated during the Meiotic Recombination Checkpoint in Response to 
DNA Rereplication 
 
Rad53 autophosphorylates in a Mec1-dependent manner to increase its kinase activity. 
One method to investigate Rad53 activity is by inspecting Rad53 species with reduced 
electrophoretic mobility, which is indicative of its phosphorylation and activation. This can be 
accomplished via western blot; however, a more sensitive method is to examine Rad53 
autophosphorylation in situ (162). Both methods were performed to assess Rad53 
phosphorylation and activation. Using the immunoblot method, a Rad53 phospho-isoform was 
only detected in HU-treated mitotic cells that were used as a positive control (Figure 2.7). Using 
the Rad53 autophosphorylation in situ method, there was a slight Rad53 activation at the 24 hour 
time point after sporulation was induced in the SIC1ΔPHA, SIC1ΔPHA dmc1Δ, and SIC1ΔPHA 
dmc1Δ rad9Δ strains. However, this activation was negligible compared to HU-induced Rad53 
30 
		
activation in mitotic cells (Figure 2.7). While the Rad53 activation in SIC1ΔP dmc1Δ cells seems 
slightly higher than in SIC1ΔP cells, the SIC1ΔPHA dmc1Δ rad9Δ cells do not exhibit a 
heightened activation compared to SIC1ΔPHA cells (Figure 2.7). Therefore, it is improbable that 
this degree of activation could have been responsible for the checkpoint especially because 
heightened Rad53 activation was not observed in the checkpoint-proficient SIC1ΔPHA dmc1Δ 
rad9Δ cells. It is also possible that aside from the meiotic recombination checkpoint, a general 
persistence of DSBs and DNA damage accumulated over time in SIC1ΔPHA dmc1Δ cells led to a 
low level of Rad9-dependent Rad53 phosphorylation.  
2.4 Discussion  
 
Previously, it was found that DMC1 deletion halts DNA rereplication induced by 
stabilization of Sic1. Further deletion of RAD17 rescued the DNA rereplication phenotype (101). 
Also, further deletion of RED1, HOP1, or MEK1 from the SIC1ΔPHA dmc1Δ genetic background 
resulted in a return to the rereplication phenotype (150). Genes involved in meiotic and mitotic 
cell cycle checkpoints that were hypothesized to be involved in prevention of DNA rereplication 
were investigated using this system. It was discovered that MEC1 and other upstream 
components of the checkpoint were required to prevent DNA rereplication. However, there was 
no evidence that certain downstream effectors that regulate meiotic progression were involved in 
this system. Strains containing mutations in genes involved in preventing DNA replication in the 
mitotic cell cycle were also examined. Phosphorylation of Dbf4 and/or Sld3 was required for full 
prevention of DNA rereplication in our system. Intriguingly, these data suggest that effectors are 
phosphorylated in a Rad53-independent manner. 
 There were clear differences in the quantity of DNA rereplication recovery in SIC1∆PHA 
dmc1Δ cells depending on which additional gene was deleted or mutated (Figure 2.10). It is  
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Figure 2.10 DNA rereplication quantified in each strain. A) The 24-hour time point sample 
from each strain was analyzed, and the gating function in WinMDI software was used to quantify 
the number of cells exhibiting more than 4C DNA content. The gating was kept constant 
between strains in each experiment. B) The number of cells exhibiting >4C DNA content in each 
strain out of 20,000 total cell counts is displayed on the y-axis. Data points from strains that fit 
our criteria for DNA rereplication are displayed as filled circles, and data points from strains that 
did not fit our criteria for DNA rereplication are displayed as open circles.  
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noted that the SIC1∆PHA dmc1∆ rad9∆ strain showed minor DNA rereplication in three 
experiments, however, the majority of the experiments showed levels of DNA rereplication 
comparable to the SIC1∆PHA dmc1∆ strain. The SIC1∆PHA dmc1∆ dbf4-4A sld3-38A strain 
showed low levels of DNA rereplication in two of the six experiments. In these two experiments, 
meiotic progression in all strains was slow. In conclusion, strains displaying lower levels of 
DNA rereplication were more prone to experimental variability.  
 Inter-experimental variability makes it problematic to be conclusive about these 
differences, but there were clear trends in regards to the mutant pathways involved. For example, 
removal of proteins that prevent both inter-sister repair and meiotic progression, such as Mek1, 
resulted in robust DNA rereplication with a significant number of cells containing >~8C DNA 
content. These experiments imply that Mek1 functions in preventing inter-sister repair, and 
subsequently retaining the checkpoint signal originating from unrepaired DSBs, to prevent DNA 
rereplication in our system. It does not appear that the Mek1 functions in preventing DNA 
replication or halting meiotic progression contribute to meiotic prevention of DNA rereplication 
in our system. In contrast to this data, mutation of genes to abolish H2A or Dbf4 and Sld3 
phosphorylation resulted in fewer cells exhibiting >~8C DNA content. This difference may be 
occurring because the degree of DNA rereplication is restricted by unrepaired and resected 
DSBs, although approximately equal γ-H2A staining was observed in the different strains 
regardless of checkpoint status. It could also be the case that more than a single checkpoint 
mechanism is involved in preventing DNA rereplication during meiosis, and only one is absent 
in some strains such as in SIC1∆PHA dmc1Δ dbf4-4A sld3-38A cells. In this way, perhaps the 
meiotic recombination checkpoint pathway in our system only controls a subset of origins. 
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Regardless, the data clearly reveal that the DNA replication machinery can be targeted and 
inhibited by the meiotic recombination checkpoint. 
The pathway that prevents DNA rereplication during the meiotic recombination 
checkpoint shares several components with mitotic cell cycle DDR checkpoint mechanisms. 
Mec1, Rad17, and presumably the entire 9-1-1 complex were required for prevention of DNA 
rereplication in our system. Notably, DNA rereplication during the mitotic cell cycle stimulates a 
Mec1- and Rad17-dependent checkpoint response that halts further DNA rereplication (163).  
Both MEC1 and RAD17 were essential for prevention of DNA rereplication in our system. 
Interestingly, slightly less DNA rereplication was observed upon deletion of MEC1 and SML1 
from SIC1∆PHA dmc1Δ cells when compared with SIC1∆PHA dmc1Δ strains lacking genes such 
as MEK1, especially with regard to cells with >~8C DNA content. It is also possible that deletion 
of MEC1 and SML1 had a minor impact on DNA rereplication in SIC1∆PHA cells. It was reported 
that dmc1Δ mec1-1 cells progress through meiosis with unrepaired DSBs (111). As proposed 
above, persistent unrepaired DSBs may influence the amount of DNA rereplication in our 
system. The function of Tel1 in preventing DNA rereplication during the meiotic recombination 
checkpoint was not examined. Tel1 is a Mec1-related PIKK that is involved in DDR pathways 
including the meiotic recombination checkpoint response (164-166). Tel1, as is the case with 
Mec1, catalyzes Hop1 phosphorylation that is required for Mek1 activation (138). Perhaps the 
DNA rereplication phenotypic difference between SIC1∆PHA dmc1Δ mec1Δ sml1Δ and 
SIC1∆PHA dmc1Δ mek1Δ cells (detected even though Mek1 normally functions downstream of 
Mec1) is because of Tel1’s function. Alternatively, downstream effectors of Mec1, besides 
Mek1, may be promoting DNA rereplication. 
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 The Mec1 binding partner Ddc2 associates with RPA bound to ssDNA and assists with 
Mec1 activation (12). RPA-bound ssDNA would be abundant in dmc1Δ cells because of highly 
resected DSBs created by Spo11 (109). Active Mec1 can then phosphorylate H2A to form γ-
H2A, which was found to be required for full prevention of DNA rereplication. DOT1, which 
encodes the enzyme that generates H3meK79, was also required for prevention of DNA 
rereplication in our system. γ-H2A was abundant and H3meK79 was likely abundant (158) in 
SIC1∆PHA cells that displayed DNA rereplication. These two histone modifications were 
necessary but not sufficient for the full checkpoint response to DNA rereplication. In mitotic 
cycling cells, particularly during the G1 DDR, these modifications and Rad6-Bre1 mediated 
histone H2B ubiquitylation required for H3meK79 are vital for Rad9 recruitment and Rad53 
activation (118,154,155). Neither RAD9 nor RAD53 were required and neither seemed to be 
involved in prevention of DNA rereplication during the meiotic recombination checkpoint 
response. It could be possible that Rad53 is activated by a mechanism that cannot be detected by 
our methods, but this seems improbable. In fact, these results are consistent with the multiple 
findings that the Rad9-Rad53 axis is not involved in the meiotic recombination checkpoint that 
prevents pachytene exit and halts progression through meiosis (109,111,123). Intriguingly, 
residues in Dbf4 and/or Sld3 that are typically targets of phosphorylation by Rad53 during the 
mitotic cell cycle and serve to prevent late origin finding (66,68) function to prevent DNA 
rereplication during the meiotic recombination checkpoint. However, there was a slight 
disagreement with mitotic cell cycle observations in regards to the strain that carries the mcm5-
bob1 allele, which eliminates the requirement for the DDK protein kinase in DNA replication 
initiation (161). This allele did not substitute for the dbf4-4A mutant allele as it was shown 
previously in the mitotic cell cycle studies (68). This difference could reflect fundamental 
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differences in regulation of DNA replication during the mitotic cell cycle and meiosis, or it could 
be because of lowered CDK activity in SIC1∆PHA cells. 
Taken together, our results suggest that a response to DNA rereplication during the 
meiotic recombination checkpoint involves a protein kinase that is activated in a similar manner 
and has functions similar to those of Rad53 during the DDR in the mitotic cell cycle (see Figure 
2.11). Mek1 would be an obvious candidate for this kinase activity since it has structural 
similarity to Rad53 and it is expressed only during meiosis (123,130,131). However, our data 
shows that Mek1 is required for prevention of DNA rereplication because of its functions in 
preventing inter-sister repair and not because of a function in preventing DNA replication. 
Furthermore, a peptide-based study looking at yeast kinase phosphorylation site specificity 
placed Rad53 and Mek1 into the same cluster, but the two kinases are not closely related and 
display clear differences in their extent of specificity (167). These data indicate that Mek1 is 
unlikely to be responsible for Dbf4 and Sld3 phosphorylation during the meiotic recombination 
checkpoint. Dun1 is another kinase with physical similarity to Rad53 and functions downstream 
of Rad53 to regulate transcription and dNTP levels after a challenge with genotoxic stress 
(53,168). However, biochemical studies propose different substrate specificities between the two 
enzymes (169-171). A comprehensive analysis of transcriptional regulation after DNA damage 
also indicates differential targeting by Rad53 and Dun1 (172). Therefore, there is no evidence to 
demonstrate that Mek1 or Dun1 would phosphorylate the same sites as Rad53 in Sld3 and Dbf4, 
suggesting that a separate kinase operates during meiosis that is similar in function to Rad53 and 
can prevent DNA replication initiation. ATR can catalyze Dbf4 phosphorylation upon replication 
stress or ionizing radiation, and this phosphorylation is important for the prevention of 
rereplication during the mitotic cell cycle (94). A mechanism where Mec1 bypasses Rad53  
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Figure 2.11 The proposed pathway that operates to prevent DNA rereplication when the 
meiotic recombination checkpoint is activated. Mec1, Mek1, Dbf4, and Sld3 operate in the 
dmc1∆-induced meiotic recombination checkpoint to prevent rereplication arising from 
Sic1∆PHA. Also shown are the functions of Mek1 in normal cells. See discussion for the possible 
kinases responsible for catalyzing Dbf4 and Sld3 phosphorylation.  
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function and directly catalyzes Dbf4 and/or Sld3 phosphorylation could be involved in the 
meiotic recombination checkpoint.  
Since small amounts of rereplication can cause gene amplification (96), it is proposed 
that rereplication could be an initiating factor in carcinogenesis. However, studying rereplication 
in human cells is difficult since it usually results in extensive DNA damage that inevitably leads 
to cell death. Methods to bypass the rereplication checkpoint lead to apoptosis or senescence 
(173). Based on this concept, it has been proposed to induce DNA rereplication as cancer 
therapy. It was found that inducing rereplication caused apoptosis in cancer cells but not in an 
immortalized non-cancer cell line (174). Perhaps human orthologs of some proteins discovered 
to be essential for prevention of DNA rereplication in our system could be targets for inhibition 
as cancer therapy. Perhaps ATR inhibitors induce rereplication in cancer cells, and this is one 
mechanism by which ATR inhibitors are effective.  
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CHAPTER 3- SYNTHETIC GENETIC INTERACTIONS BETWEEN THE DNA 
DAMAGE RESPONSE AND TRANSCRIPTION OR REPLICATION MACHINERIES 
 
3.1 Introduction 
 
3.1.1 Synthetic Genetic Interactions and their Role in Cancer Treatment 
 
An important method to study gene function and how genes fit into pathways is by 
analyzing phenotypes caused by the deletion of genes. This can be extended to studying the 
deletion of two genes at once. Synthetic genetic interactions occur when the deletion of either of 
two genes on their own does not cause a significant loss of fitness but when both genes are 
deleted concurrently, a synergistic loss of fitness (synthetic sickness) or inviability (synthetic 
lethality) occurs. Synthetic sickness is by definition a fitness defect that is greater than a 
multiplicative effect of the fitness defect of each gene deletion on its own. In functional terms, 
the deletion of one gene creates an intracellular environment that can only be handled by the 
other gene product. If the second gene is deleted, the cell cannot deal with the environment and a 
loss of fitness occurs (175). In many cases, synthetic genetic interactions can suggest that the 
genes function in related pathways. When studying genes involved in the DDR, one gene 
deletion may cause enhanced DNA damage that can only be processed in the presence of the 
other gene. When the DDR gene is also deleted, there is a buildup of DNA damage that causes 
lethality or reduced fitness. 
The concept of synthetic lethality is important in the treatment of cancer in order to 
establish what combination treatments may be effective and what treatments will selectively kill 
cancer cells while sparing normal cells. This has been shown definitively in the treatment of 
BRCA1 or BRCA2 mutated breast cancers with (poly ADP ribose polymerase) PARP inhibitors. 
PARP is a family of proteins involved in several mechanisms but most importantly the base 
excision repair pathway that repairs ssDNA damage (176). One theory is that when a PARP 
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inhibitor is administered, ssDNA damage cannot be effectively repaired, so when the replication 
machinery encounters this damage, the ssDNA damage is converted into a DSB. This damage 
can be repaired in cells with functional DSB repair pathways, but in cancer cells with aberrant 
DSB repair such as in BRCA1/2 mutated cancers, this damage cannot be repaired, which 
subsequently causes apoptosis (177). PARP inhibitors are also theorized to trap PARP at 
locations of damage, resulting in stalled replication forks, which ultimately leads to DSB 
formation. This damage can be repaired in normal cells, but cancer cells with dysfunctional 
BRCA genes cannot repair the damage and succumb to cell death (178). ATM or RAD51 
mutations also confer an increased sensitivity to PARP inhibition (179).  
A more recent example of synthetic lethality is in the treatment of mismatch repair-
deficient solid tumors with an anti-PD-1 antibody. PD-1 functions in the immune checkpoint to 
negatively regulate the immune response, so blocking PD-1 unleashes the immune system to 
attack and kill cancer cells. Cancer cells with mismatch repair deficiency contain a large 
proportion of neoantigens, which makes them more recognizable to the immune system, and 
therefore more susceptible to anti-PD-1 antibody treatment (180). Mutations in genomic 
instability genes are commonly seen in the early stages of carcinogenesis (181-183), which then 
predisposes cells to gain further mutations and leads to transformation. Genes that synthetically 
interact with these mutated genomic instability genes could be good targets for drug inhibition 
since cancer cells should be more sensitive to treatment than normal cells. Also, since mutation 
of genomic instability genes is an early event, there should be less heterogeneity with this 
mutation between cells. As a result, most cancer cells should be sensitive to treatment.  
One well established synthetic genetic interaction is between ATR/MEC1 and a related 
PIKK, ATM/TEL1. There is a synergistic sensitivity of mec1 tel1 yeast double mutant strains to 
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DNA damaging drugs (165). Human cancer cells that have dysfunctional ATM are 
hypersensitive to ATR inhibitors (184,185), and siRNA that targets ATM sensitizes cells to ATRi 
(186), both indicating a synthetic sick effect between ATR and ATM in human cancer cells. This 
indicates synthetic genetic interactions can be conserved between budding yeast and higher 
eukaryotes. A number of other cell cycle and DNA repair gene deficiencies have been found to 
induce synthetic lethality with ATR inhibitors, including ERCC1 (187), XRCC1 (188), CDC25A 
(189), and TP53 (184,190). Mutations in a subunit of the SWI/SNF chromatin-remodeling 
complex, ARID1A, also induced synthetic lethality with an ATR inhibitor (186).  
 Synthetic genetic interactions are most easily studied in yeast because of the genetic 
malleability of the model system, the fast doubling time, low cost, relatively small genome, and 
ease of performing high-throughput screens. Most major signaling pathways, including the DDR 
pathways, are highly conserved from yeast to humans (191). Some studies indicate that synthetic 
genetic interactions are poorly conserved between yeast and higher eukaryotes (192-194). 
However, others show that synthetic genetic interactions are highly conserved between yeast and 
higher eukaryotes (195-199).  
A synthetic genetic array (SGA) is a high-throughput method of examining synthetic 
genetic interactions using robotic manipulation of yeast strains. A haploid strain with a gene 
mutation of interest is mated with haploid strains from the gene deletion library, which consists 
of ~5000 strains each with a single gene deletion. Heterozygous diploid double mutants are then 
sporulated to produce haploids. Double mutant haploids are then selected using selection media 
and colony size is measured (200,201). If the colony size, which is indicative of overall fitness, is 
smaller than what would be expected by multiplying the effects of the two single gene deletions, 
a negative synthetic genetic interaction can be inferred (202). Negative genetic interactions are 
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especially important because they predict functional interactions that tend to interrupt redundant 
pathways (203,204). SGAs have been performed using many different combinations of non-
essential gene deletions (200,203). Advances in technology are now allowing the study of 
essential genes via SGA. This is done by using conditionally down-regulated genes or by 
studying hypomorphs (205,206). A SGA screen using a mec1 null strain performed in 
collaboration with researchers at University of Toronto uncovered genes involved in 
transcriptional regulation, including subunits of the Mediator complex, and genes involved in 
DNA replication and repair (see Results).  
3.1.2 Transcriptional Regulators and their Role in Cancer 
 
 As described further in the results section, a SGA screen was conducted using the mec1∆ 
strain and known and novel genetic interactions were revealed. Processes related to those 
interactions are described here. Transcription is a tightly regulated process that mediates protein 
levels in the cell. RNA polymerase II is responsible for transcription of mRNA and some non-
coding RNA. The Mediator complex is a crucial component of transcriptional regulation because 
it serves as physical communication between gene-specific regulatory factors and the RNA 
polymerase II complex (207-209). Notably, the Mediator complex is highly conserved from 
yeast to humans. It is made up of more than 20 subunits that are divided into four modules. The 
head and middle modules interact directly with RNA polymerase II, the tail module interacts 
directly with transcription factors, and the detachable kinase module can phosphorylate RNA 
polymerase II in order to repress transcription (210,211). The Mediator complex is not only 
involved in initiation of transcription, but also elongation and termination (212).  
Many subunits of the Mediator complex have been associated with cancer. Mediator 
complex subunit overexpression has been linked to breast, prostate, and colon cancers (213). One 
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study looked at Mediator subunit expression of all subunits in osteosarcoma cell lines and 
compared them to a normal osteoblast cell line. In general, subunits in the head module were 
overexpressed and subunits in the kinase module were underexpressed in the cancer cells. 
Interestingly, the MED20 subunit shows ~20 fold overexpression in the cancer cells (214). 
MED9 and MED20 showed alterations in patient samples of several cancer types. MED20 
amplification occurred in ~17% of breast cancer patient samples (215), ~7% of prostate cancer 
samples (216), and ~4% of lung adenocarcinoma patients (217). MED9 was amplified in ~17% 
of breast cancer patient samples (215) and was deleted in two of twelve breast adenoid cystic 
carcinoma samples examined (218).  
MED19 expression was higher in bladder cancer tissue than in paired normal tissue and 
was associated with histopathological grade. Knockdown of MED19 caused tumor cell growth 
inhibition in vitro and in vivo (219). MED19 was overexpressed in laryngocarcinoma patient 
samples compared to normal tissue, and knockdown of MED19 in a laryngeal carcinoma cell line 
caused growth inhibition in vitro and in vivo (220). Similarly, MED19 was knocked down in 
prostate cancer cell lines and caused decreases in proliferation and migration. MED19 was 
shown to be involved in upregulation of genes involved in cell cycle, cell proliferation, and 
epithelial to mesenchymal transition (221). Overexpression of Mediator subunits in cancer cells 
suggests possible oncogenic properties of certain Mediator subunits in certain malignancies. 
Interestingly, other Mediator subunits may be acting as tumor suppressors. Loss of MED12 has 
been associated with an epithelial to mesenchymal transition phenotype and tumor cell resistance 
to multiple small molecule inhibitors used in cancer therapy, including ALK, EGFR, BRAF, and 
MEK inhibitors (222,223). Mutations in the MED12 subunit were found to occur in 67% of 
uterine leiomyoma, a benign tumor (224). When these mutations were created in a mouse model, 
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it caused the mice to develop lesions consistent with leiomyoma. They found that the mutation 
acted in a dominant fashion to increase genomic instability (225).  
Several Mediator subunits were shown to be essential for acute myeloid leukemia (AML) 
cell proliferation and knockdown of these subunits resulted in differentiation of leukemic blasts 
(226). A novel inhibitor of the CDK8 kinase subunit of the Mediator complex has recently been 
developed as a therapy for AML. The inhibitor was found to reduce tumor growth in a xenograft 
mouse model (227). This indicates that certain Mediator subunits may be viable targets in the 
treatment of certain cancers, such as AML.  
The Mediator complex and BRD4, a member of the bromodomain and extraterminal 
domain (BET) family, were found to co-occupy chromatin at super-enhancers, where high levels 
of transcriptional cofactors are bound to large enhancer regions. An inhibitor of the BET family 
(BETi), which is thought to globally suppress transcription, was found to evict Mediator from 
super-enhancers of genes that promote carcinogenesis, such as MYC (226,228). Prolonged 
binding of the MED1 subunit of the Mediator complex to chromatin was shown to be a 
resistance mechanism to BETi (229). This inhibitor and a structurally distinct BETi were also 
found to synergize with ATR inhibitors in Myc-induced lymphoma cell lines and a syngeneic 
tumor transplant mouse model (230). If general transcriptional inhibitors synergize with ATR 
inhibitors, then inhibition of Mediator complex subunits may be synergistic with inhibition of 
ATR. The Mediator complex has an enormous number of subunits and not all of them are 
essential, which would make it less likely that inhibition of a non-essential subunit would 
produce toxicity towards normal cells. Also, specific subunits have been shown to be necessary 
for the downstream effects of certain signaling pathways. For example, MED12/Srb8 and 
MED13 are crucial for the activation of WNT signaling, a pathway that is dysregulated in a 
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variety of cancers (231). If a specific inhibitor of MED12 or MED13 were developed, this could 
inhibit WNT signaling without affecting other essential signaling pathways, which may result in 
minimal adverse effects.  
 Transcriptional regulation has been linked with DNA damage in several pathways. An 
important endpoint of the DDR is transcriptional regulation. An example of which is the p53 
tumor suppressor, which is activated in response to DNA damage and subsequently works as a 
transcription factor to increase transcription of a number of genes, including those involved in 
DNA repair (232). In yeast, Mec1 responds to DNA damage by activating downstream 
transcription factors, which then regulate transcription (233,234). In response to the DNA 
alkylating agent, methyl methanesulfonate, Mec1 regulates the transcription of more than 600 
genes through the activation of at least nine different transcription factors. As discussed earlier, 
Mec1 is involved in resolving conflicts between transcription and replication machineries by 
evicting transcription machineries and by resolving stalled replication forks (42,62). Another 
connection between transcription and DNA damage is transcription-coupled DNA repair. DNA 
damage can often interfere with the progression of the transcription machinery. The RNA 
polymerase machinery can mediate recruitment of DNA repair proteins to the damage, which 
perform transcription-coupled DNA repair so that transcription can resume (235).  
3.1.3 Genes Involved in DNA Replication and Repair and their Role in Cancer 
 
A central component of DNA replication is DDK, composed of DBF4 and CDC7, which 
is essential for origin firing. The DDK complex is associated with cancer in several ways. DDK 
is overexpressed in many tumor cells and DDK overexpression was correlated with loss of p53 
in primary breast cancers, indicating that DDK overexpression may be a common phenomenon 
in human cancers (236-243). Overexpression of DBF4 is correlated with poor prognosis in 
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cutaneous melanoma patients (244). CDC7 overexpression in lung adenocarcinoma is correlated 
with worse survival (245). Similar to the dependence of cancer cells on the ATR pathway to 
avoid apoptosis, it is thought that cancer cells can also become dependent on DDK (246). 
RAD18, which is involved in translesion synthesis, and RAD54, which is involved in 
homologous recombination, are synthetic lethal in chicken cells (247). DDK is involved in the 
translesion synthesis pathway (80), and could be a target to inhibit in BRCA1/2 mutant cancer 
cells that have defective homologous recombination.  
Interestingly, siRNA inhibition of DDK in HeLa cells caused p53-independent apoptosis, 
while primary fibroblasts experienced p53-dependent cell cycle arrest (248). DDK is associated 
with chemoresistance and higher frequency of mutations (245). Selective inhibitors of DDK have 
been developed as anti-cancer agents. The rationale behind their use is that inhibition of DDK 
should prevent phosphorylation of the MCM helicase and thereby prevent DNA replication. If 
there is no replication fork, the DDR cannot sense a problem and therefore is not activated. DNA 
damage then builds up and mitotic catastrophe occurs, eventually resulting in cell death (249). 
PHA-767491 is a DDKi that was found to prevent MCM2 phosphorylation and induce DSBs. 
CHK1 was not activated, indicating that the replication stress checkpoint was not activated. 
Tumor growth inhibition and few side effects were seen in a mouse xenograft model of AML 
(250). PHA-767491 was also found to inhibit glioblastoma cell line proliferation and trigger 
apoptosis. It was further found to inhibit migration and invasion, which makes this drug 
promising at reducing metastasis (251). PHA-767491 was found to synergize with 5-fluorouracil 
in hepatocellular carcinoma cells, and the combination treatment caused more apoptosis than 
either single drug alone (252). However, PHA-767491 has off-target effects on CDK9 (250). 
Another DDKi, XL-413, was seen to be more specific for the DDK complex. Treatment caused 
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cell cycle arrest in Colo-205 cells and tumor growth inhibition in a Colo-205 mouse xenograft 
model (253). However, another study found that XL-413 was effective in Colo-205 cells but had 
little effect on cell viability in the other seven cell lines they tested. They found that PHA-
767491 and XL-413 had similar activity on purified DDK, indicating that XL-413 may have low 
bioavailability in most cell lines (236). XL-413 was previously used in clinical trials; however, 
trials were suspended because of an “unfavorable pharmacologic profile” (SEC Research and 
Collaboration Agreements December 31, 2012). There are several novel CDC7 inhibitors that 
have been found to be selective and potent in vitro (254,255). There are also clinical trials 
assessing the use of novel CDC7 inhibitors as treatments for solid cancers, but the preclinical 
data has not been published regarding these compounds. DDK seems to be a promising target for 
inhibition as cancer therapy, and it will be important to discover other novel and established 
therapies that may work well in combination with DDK inhibitors.  
Another important gene in DNA replication and DNA repair is RAD27, the yeast 
orthologue of flap structure-specific endonuclease 1 (FEN1). The functions of the protein 
products of these genes are to remove 5’ overhanging flaps on Okazaki fragments during DNA 
replication and to process similar structures during base excision repair. A synthetic genetic 
interaction between MEC1 and RAD27 has been previously observed in S. cerevisiae (256). 
However, high-throughput screens performed using siRNA in human cancer cells failed to 
uncover this synthetic interaction, either looking for sensitivity to FEN1 inhibitors (257) or 
sensitivity to ATR inhibitors (186). Two germ line mutations in FEN1 cause an increased 
frequency of lung and gastrointestinal cancers (258,259). Although classically thought of as a 
tumor suppressor since FEN1 is involved in maintaining genomic integrity, FEN1 expression is 
upregulated in a number of different cancer types (260-263). High levels of FEN1 were also 
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associated with poor breast cancer survival (264). This could be due to the high rate of DNA 
replication in cancer cells that requires an overexpression of proteins involved in DNA 
replication. Inhibitors of FEN1 have been developed as a cancer therapy and have been shown to 
induce the DDR, but the inhibitors are in the early phases of preclinical testing (265-267). 
Important genes for this chapter along with their human orthologs and simplified functions are 
listed in Table 3.1.  
3.2 Materials and Methods 
 
3.2.1 Strains 
 
 All single deletion yeast strains used in this study are from the deletion set (144) (GE 
Dharmacon). The wild type yeast strain BY4741 was used as a control for the single deletion 
studies. In mec1∆ deletion strains, the MEC1 allele was replaced with a LEU2 marker that allows 
for growth in media lacking leucine. The SML1 allele was replaced with an allele that allows for 
resistance to nourseothricin (clonNAT). Genes of interest (e.g. CSE2) were replaced with the 
KANMX4 allele that provides resistance to G418. All double mutant strains contain the indicated 
gene mutations in the BY4741 background with the addition of the can1∆::MFA1pr-HIS3 lyp1 
sml1∆ alleles. The only exception is that the sml1∆ strain is from the deletion set and contains 
the sml1∆ allele in the BY4741 background. However, the sml1∆ strain containing the 
can1∆::MFA1pr-HIS3 lyp1 alleles in the BY4741 background was also analyzed and there was 
no difference in growth rate. A multicopy plasmid, pYGWRNH1, was graciously received from 
Andrés Aguilera that contains the RNH1 gene under the control of the GAL1 promoter (268). 
This plasmid was transformed into strains using the LiAc/ss carrier DNA/PEG method as 
described (269). 
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Yeast Gene  Human Ortholog Role 
MEC1 ATR DDR Protein Kinase 
TEL1 ATM DDR Protein Kinase 
CSE2 MED9 Mediator Subunit 
SRB2 MED20 Mediator Subunit 
DST1 TCEA1 Transcriptional Regulation 
HTZ1 H2A.V, H2A.Z Transcriptional Regulation 
DBF4 DBF4/ASK DNA Replication 
RAD27 FEN1 DNA Replication 
 
 
Table 3.1 List of important genes studied in Chapter 3. MEC1 and genes confirmed to 
synthetically interact with MEC1 in yeast are listed along with their human orthologs. A 
simplified version of the functions of these genes is also listed.  
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3.2.2 Synthetic Genetic Arrays 
 
 The initial high-throughput synthetic genetic array (SGA) analysis was performed at 
University of Toronto in collaboration with the Charles Boone and Grant Brown laboratories. 
Details about the protocol are as described (201). Briefly, MATα mec1∆ sml1∆ and sml1∆ strains 
were mated with strains from the MATa deletion set library. The more recent screen also 
included MATa hypomorphs and conditional mutants. Heterozygous diploids were then selected 
and sporulated. MATa haploids containing mec1∆ sml1∆ or sml1∆ and the gene mutation of 
interest were then selected. Cells were germinated and colonies were imaged. Image analysis 
software was then used to analyze the colony sizes, and if the colony size was smaller than a 
multiplicative effect of both gene mutations, a negative genetic interaction was inferred.  
3.2.3. Random Spore Analysis 
 
 Media preparation and random spore analysis were performed as described (270). 
Briefly, mec1∆ sml1∆ and sml1∆ MATα strains were mated with single mutant deletion MATa 
strains. Heterozygous diploids were then selected with YEPD + G418/clonNAT (YPD 
supplemented with 120 mg/L adenine, 0.2 mg/L G418, 0.1 mg/L clonNAT) and sporulated for 
five days at 22°C on solid enriched sporulation medium or liquid SPO++ medium (1.5% (w/v) 
potassium acetate, 0.25% (w/v) yeast extract, 0.25% (w/v) glucose, supplemented with 40 mg/L 
each of adenine, uracil, and tyrosine, 20 mg/L each of histidine, leucine, lysine, tryptophan, 
methionine, and arginine, 100 mg/L phenylalanine, and 350 mg/L threonine). Spores were then 
plated on SD/MSG –his/arg/lys + canavanine/thialysine, SD/MSG –his/arg/lys + 
canavanine/thialysine/G418, SD/MSG –his/arg/lys + canavanine/thialysine/clonNAT, SD/MSG 
–his/arg/lys + canavanine/thialysine/G418/clonNAT, SD/MSG –his/arg/lys/leu + 
canavanine/thialysine/clonNAT, and SD/MSG –his/arg/lys/leu + 
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canavanine/thialysine/G418/clonNAT that each select for a different genotype. Plates were then 
scanned for images after three days at 30°C (or four days at 23°C in the case of dbf4 mutants). 
Tetrad analysis was performed similarly except after sporulation, tetrads were dissected from 10 
asci and germinated on solid YPD at 30°C. The plate was imaged and ImageJ was used to 
determine colony size. The colonies were then transferred to media that select for the different 
gene deletions to determine the genotype of the colonies.  
3.2.4 Growth Rate 
 To assess growth rate, all growth was performed at 30°C (or 23°C in the case of the dbf4 
mutant experiments). Frozen stocks of strains were streaked onto YPD solid media and incubated 
for at least three days. Single colonies were then transferred to SD/MSG (complete) liquid media 
and incubated for approximately 24 hours. Overnight cultures were then diluted to OD600 of 0.2 
and OD600 was measured at the indicated time points by spectrophotometry (Pharmacia Biotech). 
3.2.5 HU Sensitivity  
 
 HU sensitivity experiments were performed by streaking strains from frozen stocks onto 
solid YPD media. Single colonies were transferred to liquid YPD media (or synthetic complete 
media lacking uracil for the strains carrying the RNH1 plasmid) and grown overnight at 30°C (or 
23°C in the case of the dbf4 mutant experiment). Overnight cultures were normalized to the 
strain with the lowest OD600 and serially diluted (1:10, 1:100, 1:1000, and 1:10000). Five µl of 
each dilution was spotted onto SD/MSG (complete), SD/MSG (complete) + HU, SD/MSG/2% 
Galactose (complete), and SD/MSG/2% Galactose (complete) + HU plates. 100 mM HU was 
used for single mutant experiments, and 1 mM HU was used for double mutant experiments. In 
the cases of dbf4 and rad27 single mutants, cultures were spotted onto YPD and YPD + 100mM 
HU. dbf4 and rad27 double mutants were spotted onto YPD and YPD + 1 mM HU. Plates were 
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grown at 30°C (or 23°C in the case of the dbf4 mutant experiment) and scanned after sufficient 
growth.  
3.2.6 DNA Content 
 
 Flow cytometry was used to measure DNA content. Overnight cultures were brought to 
an OD600 of 0.2 and grown at 30°C (or 23°C in the case of the dbf4 experiment) for two hours. 
Cultures were arrested with 2.5 µM alpha factor for two hours at 30°C (or 23°C in the case of the 
dbf4 experiment) then alpha factor was removed and cells were washed with sterile water. 
Samples were taken at the indicated time points, cells were fixed, and DNA was stained with 
SYBR green I as in chapter 2 methods. The BD Canto II flow cytometer at the Microscopy, 
Imaging, and Cytometry Resources Core at Wayne State University School of Medicine was 
used for analysis  
3.2.7 Cell Culture 
 
 Our human NSCLC work was done in Dr. Stephen Patrick’s lab using the A549, H460, 
and H1299 cell lines. All incubations were performed at 37°C in 5% CO2. A549 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM)/high glucose media supplemented 
with 10% fetal bovine serum, 1% penicillin/streptomycin solution, 1X minimal essential medium 
(MEM) non-essential amino acid solution, and 1X HEPES buffer. H460 and H1299 cells were 
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin solution.  
3.2.8 siRNA, shRNA, and Drug Treatments 
 
 Transfection of a non-targeting control shRNA and shRNA against MED9, MED20, 
DBF4, and FEN1 was performed as previously described (271) except that we used a midi prep 
kit (Qiagen). For the siRNA knockdown experiments, 200,000 cells were seeded, incubated 
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overnight, and transfected with 5 µM of a pooled set of four siRNA in complete media with 
0.2% DharmaFECT reagent #4 (GE Dharmacon) for 24 hours. The transfection was repeated for 
another 24 hours. Cells were then treated with the indicated amounts of ATR inhibitor, VE-822 
(Selleck Chemicals) for four hours in serum-free media. After treatment, media was replaced 
with complete media and incubated until colonies formed. Cells were then stained with crystal 
violet (1% w/v crystal violet in 80% ethanol solution) and colonies with more than 50 cells were 
counted. Percent colony survival was calculated based on untreated cells. Error bars were plotted 
using standard error. Dual VE-822 and XL-413 (Tocris) treatment was done similarly except the 
treatments were done in complete media for 24 hours. Synergy was assessed by treating A549, 
H460, and H1299 cells with varying concentrations of ATRi, DDKi, or the two in combination at 
varying concentrations but an identical ratio for 24 hours in complete media. Colonies were 
counted and values were used to create combination index values and to calculate the doses 
required to affect 90% of cells using the CompuSyn program (272).  
3.2.9 Protein  
 
 Yeast western blotting analyses were performed as in aim 1. Human cells were washed 
with 1X PBS, and pellets were stored at -80°C. Protein was extracted in lysis buffer (10 mM Tris 
pH 8.0, 120 mM NaCl, 0.5% NP-40, 1 mM EDTA) containing protease inhibitors (0.5 M phenyl 
methyl sulphonyl fluoride, 1 mg/ml Leupeptin, 1 mg/ml pepstatin A) for 30 minutes on ice. 
Protein resolution and transfer were performed as in chapter 2 methods. Antibodies included 
anti-MED9 (Abcam), anti-DBF4 (Bethyl), anti-FEN1 (Santa Cruz Biotechnology), anti-PARP1 
(Proteintech), MCM2 (Bethyl), anti-Phospho-MCM2 (S53) (Bethyl), and anti-α-tubulin (Sigma-
Aldrich). Secondary antibodies were the same as described in aim 1 except we also used IRDye 
800-conjugated anti-mouse (Rockland).  
53 
		
3.3 Results 
 
3.3.1 Synthetic Interactions between MEC1 and Transcription Regulators in S. cerevisiae 
 
In collaboration with Charles Boone and Grant Brown at University of Toronto, a MEC1 
SGA screen was performed. The mec1∆ sml1∆ and sml1∆ deletion strains were screened with 
the gene deletion strain library. The screen resulted in ~200 prospective genes that synthetically 
interact with MEC1 but not SML1 (Table 3.2). A previous SGA screen involving MEC1 only 
discovered 16 synthetic genetic interactions (78). Ten of these interactions were also discovered 
using our screen but two of them were found to interact with SML1 so were discarded from the 
analysis. As expected, Gene Ontology analysis showed that genes involved in different aspects 
of DNA metabolism, including DNA repair, the DDR, and DNA recombination likely 
synthetically interact with MEC1. Interestingly, 36 genes involved in transcription from the RNA 
polymerase II promoter were found to likely synthetically interact with MEC1 (Table 3.2). An 
interesting subset of the synthetic genetic array results includes genes that encode subunits of the 
Mediator complex (Table 3.3). Approximately half of the Mediator subunits are essential for 
viability (273). Since strains with mutations in essential genes were not included in this screen, 
there was considerable enrichment for Mediator subunits discovered in the MEC1 screen. 
Mediator subunits were a focus of the work, but transcriptional regulators HTZ1 and DST1 were 
also studied. HTZ1 is a histone variant and DST1 is a general transcription elongation factor.  
 A subset of the genes that were identified in our screen was selected for further study. 
Random spore analysis was performed to confirm the synthetic genetic interactions (see 
Methods). Random spore analysis has confirmed the synthetic genetic interactions between 
MEC1 and CSE2, SRB2, DST1, and HTZ1 (Figures 3.1, 3.2, 3.3, 3.4 and Table 3.2). HHO1 was 
used as a negative control to ensure that the small colony size of the triple mutants was not due  
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Table 3.2 Gene Ontology analysis of genes that synthetically interact with MEC1. The P-value is 
derived from a c2 test where the percentage of genes with a certain gene ontology annotation out 
of the total number of genes revealed from the synthetic genetic array is compared with the 
frequency of genes containing the same gene ontology annotation out of the entire genome. 
Genes exhibiting possible synthetic interactions with leu2 were not excluded from this analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   Yeast Gene Protein description Random Spore Analysis Human Gene 
55 
		
 
Table 3.3 Genes of interest confirmed to synthetically interact with MEC1 with the initial SGA 
screen. 
 
 
 
 
 
 
 
 
 
 
CSE2 Mediator subunit, middle module                  yes MED9 
NUT1 Mediator subunit, middle module                  yes MED5 
SRB2 Mediator subunit, middle module                  yes MED20 
SRB8 Mediator subunit, Cdk8 module                  yes MED12 
HTZ1 Histone variant H2AZ                 yes H2A.V, H2A.Z 
DST1 General transcription factor TFIIS                 yes TCEA1 
56 
		
 
 
 
 
Figure 3.1 Random spore analysis validates the interaction between MEC1 and CSE2 using 
the cse2∆ allele. Top panel) A haploid MATa cse2∆ strain was mated with a mec1∆ sml1∆ 
MATα haploid strain. The heterozygous diploid strain was then sporulated and plated onto media 
that selects for certain MATa mutants and left to germinate. Bottom panel) A haploid MATa 
cse2∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto selection 
media to ensure the synthetic interaction was not between CSE2 and SML1. 
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Figure 3.2 Random spore analysis validates the interaction between MEC1 and SRB2 using 
the srb2∆ allele. Top panel) A haploid MATa srb2∆ strain was mated with a mec1∆ sml1∆ 
MATα haploid strain. The heterozygous diploid strain was then sporulated and plated onto media 
that selects for certain MATa mutants and left to germinate. Bottom panel) A haploid MATa 
srb2∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto selection 
media to ensure the synthetic interaction was not between SRB2 and SML1. 
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Figure 3.3 Random spore analysis validates the interaction between MEC1 and DST1 using 
the dst1∆ allele. Top panel) A haploid MATa strain containing the dst1∆ allele was mated with a 
mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then sporulated and 
plated onto media that selects for certain MATa mutants and left to germinate. Bottom panel) A 
haploid MATa dst1∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated 
onto selection media to ensure the synthetic interaction was not between DST1 and SML1. 
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Figure 3.4 Random spore analysis validates the interaction between MEC1 and HTZ1 using 
the htz1∆ allele. Top panel) A haploid MATa strain containing the htz1∆ allele was mated with a 
mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then sporulated and 
plated onto media that selects for certain MATa mutants and left to germinate. Bottom panel) A 
haploid MATa htz1∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated 
onto selection media to ensure the synthetic interaction was not between HTZ1 and SML1. 
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to an artifact of the media. Indeed, the colony size of the hho1∆ mec1∆ sml1∆ strain is similar to 
the size of wild type colonies (Figure 3.5). The random spore analysis method was also used to 
confirm the synthetic interaction between TEL1 and MEC1 (Figure 3.6), which was previously 
established (165) and identified in our screen. Another method to verify synthetic genetic 
interactions is to perform tetrad dissections on diploids heterozygous for the two gene mutations. 
Tetrad analysis with the heterozygous cse2∆ mec1∆ strain showed that cse2∆ mec1∆ haploids 
form smaller colonies than single or double mutants, again verifying the synthetic sickness 
phenotype (Figure 3.7).  
A more quantitative approach to measuring the genetic interactions we are interested in is 
performing growth rate analysis of the single, double, and triple mutant strains. In each case, the 
double mutant strain (e.g. cse2∆ mec1∆) grew considerably slower than the wild type or single 
mutant strains (Figures 3.8, 3.9, 3.10, 3.11). This quantitatively confirms the genetic interactions 
between MEC1 and CSE2, SRB2, DST1, and HTZ1.  
Clearly, there are genetic interactions between genes involved in transcription or DNA 
replication and the DDR. Therefore, MEC1 may be offering some protection after Mediator 
subunits or genes involved in DNA replication are deleted. We hypothesized that deletion of 
transcription genes causes DNA damage that can only be repaired by a pathway involving 
MEC1. A mutation in SRB2 causes sensitivity to long-term treatment with the alkylating agent 
methyl methanesulfonate (274). Deletion of SRB2 also makes cells more sensitive to methyl 
methanesulfonate (275), indicating that SRB2 defects may cause a defect in DNA repair. Perhaps 
DNA damage builds up when certain Mediator subunits are mutant because of decreased 
transcription of DNA repair genes. Deletion of the MED12 subunit of the Mediator complex 
resulted in increased genomic instability (personal correspondence, Aleksandar Rajkovic), and if  
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Figure 3.5 Random spore analysis was performed to verify that HHO1 and MEC1 do not 
synthetically interact as a negative control. Top panel) A haploid MATa hho1∆ strain was 
mated with a mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then 
sporulated and plated onto media that selects for certain MATa mutants and left to germinate. 
Bottom panel) A haploid MATa hho1∆ strain was mated with a sml1∆ MATα haploid strain, 
sporulated, and plated onto selection media.  
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Figure 3.6 Random spore analysis confirms the TEL1 and MEC1 synthetic interaction as a 
positive control. Top panel) A haploid MATa tel1∆ strain was mated with a mec1∆ sml1∆ MATα 
haploid strain. The heterozygous diploid strain was then sporulated and plated onto media that 
selects for certain MATa mutants and left to germinate. Bottom panel) A haploid MATa tel1∆ 
strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto selection media 
to ensure the synthetic interaction was not between TEL1 and SML1. 
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Figure 3.7 Tetrad dissection of a heterozygous cse2∆ mec1∆ sml1∆ strain validates the 
synthetic genetic interaction between CSE2 and MEC1. A haploid MATa cse2∆ strain was 
mated with a mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then 
sporulated, and 10 asci were dissected and left to germinate on rich media. The plate was then 
replica plated to media that selects for the cse2∆ mec1∆ sml1∆ genotype, and a red circle denotes 
these cells.  
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Figure 3.8 Growth rate of single and double mutants in the sml1∆ background verifies the 
synthetic genetic interaction between CSE2 and MEC1. Cells were brought to 0.2 OD600 in 
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular 
intervals to determine approximate cell density. Three independent experiments were performed, 
and a representative experiment is shown.  
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Figure 3.9 Growth rate of single and double mutants in the sml1∆ background verifies the 
synthetic genetic interaction between SRB2 and MEC1. Cells were brought to 0.2 OD600 in 
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular 
intervals to determine approximate cell density. Three independent experiments were performed, 
and a representative experiment is shown. 
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Figure 3.10 Growth rate of single and double mutants in the sml1∆ background verifies the 
synthetic genetic interaction between DST1 and MEC1. Cells were brought to 0.2 OD600 in 
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular 
intervals to determine approximate cell density. Three independent experiments were performed, 
and a representative experiment is shown. 
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Figure 3.11 Growth rate of single and double mutants in the sml1∆ background verifies the 
synthetic genetic interaction between HTZ1 and MEC1. Cells were brought to 0.2 OD600 in 
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular 
intervals to determine approximate cell density. Three independent experiments were performed, 
and a representative experiment is shown. 
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other Mediator subunits behave similarly, would lend credence to this hypothesis. Based on the 
genetic interactions between transcription genes and MEC1 and the hypothesis that loss of 
transcription genes leads to DNA damage, Mec1 should be activated in strains lacking 
transcriptional regulation genes. Mec1 catalyzes phosphorylation of a number of substrates in 
order to initiate the DDR, so examining phosphorylation of these protein substrates can give us 
an idea of whether or not Mec1 has been activated. Mec1 catalyzes phosphorylation of H2A 
early in the DDR to generate λ-H2A, which is also widely used as a marker for DNA DSBs 
(79,80). Contrary to our hypothesis, λ-H2A levels were undetectable in Mediator subunit 
deletion strains (Figure 3.12). λ-H2A is usually only correlated with DNA DSBs, while Rad53 is 
phosphorylated in response to many types of DNA damage. So, unless large increases of DNA 
DSBs are initiated in response to loss of transcription genes, then Rad53 may be a better 
indicator of Mec1 activation. Mec1 phosphorylates Rad53, which then leads to 
autophosphorylation and activation of Rad53 (81). An antibody that recognizes both the 
phosphorylated and unphosphorylated forms of Rad53 was used to examine Mec1 pathway 
activity. Unexpectedly, Rad53 expression was approximately equal between wild type and 
Mediator subunit deletion strains, and Rad53 phosphorylation was undetectable (Figure 3.13). 
This indicates that the Mec1 DDR pathway is not activated in strains lacking certain Mediator 
subunits. However, the western blotting methods to detect λ-H2A and Rad53 phosphorylation 
may not be sensitive enough to detect small differences in DNA damage. We hypothesized that 
Mediator subunit deletion is causing replication stress or conflicts between transcription and 
replication machineries that requires Mec1 to resolve. This could be the reason for the higher 
mutation frequency observed in the srb2∆ strain (276). Based on this hypothesis, Mediator  
 
69 
		
 
 
 
Figure 3.12 λ-H2A expression in synchronized wild type and single mutant strains. 
Overnight cultures were brought to 0.2 OD600 and grown at 30° C for two hours in YPD. Cells 
were synchronized in G1 phase by incubating cells with 2.5 µM alpha factor in YPD for two 
hours at 30°C. Alpha factor was removed and cells were placed back into YPD and samples were 
taken at indicated time points. 0 and 24-hour YGB604 (SIC1∆PHA dmc1∆) samples from a 
synchronous sporulation experiment were used as a positive control for λ-H2A expression. 
Protein was isolated from these samples and λ-H2A and tubulin expression was visualized via 
western blot. 
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Figure 3.13 Rad53 expression in synchronized wild type and single mutant strains. 
Overnight cultures were brought to 0.2 OD600 and grown at 30°C for two hours in YPD. Cells 
were synchronized in G1 phase by incubation with 2.5 µM alpha factor in YPD for two hours at 
30°C. Alpha factor was removed and cells were placed back into YPD and samples were taken at 
indicated time points. Strains treated with 100mM HU for 0 and 90 minutes were used as 
controls. YGB138 (WT) and YGB814 (rad53∆) were used as positive and negative controls, 
respectively. Western blot was then used to visualize Rad53 and tubulin expression. 
*a non-specific band. 
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subunit deletion strains would show increased sensitivity to a compound that induces replication 
stress.  
 HU inhibits ribonucleotide reductase, the enzyme that catalyzes the rate-limiting step in 
the synthesis of deoxyribonucleotides. This inhibition reduces the deoxynucleoside triphosphate 
pools, which are necessary for proper DNA synthesis during S phase (277). Therefore, a 
heightened sensitivity to HU indicates a defect in S phase when DNA is replicating. A previous 
study found a synthetic genetic interaction between MEC1 and HPR1, which is involved in 
mRNA metabolism and export. Double mutant strains showed a hypersensitivity to HU 
compared with either single mutant, which indicates an S-phase specific effect in the double 
mutant. The hpr1∆ strain was ultimately found to show an increase in R-loop formation (268). 
Experiments were performed to examine HU sensitivity of single and double mutants of MEC1 
and genes involved in transcription. First, any strain containing mec1∆ sml1∆ was extremely 
sensitive to HU, which was established previously (39,113). The htz1∆ and srb2∆ single mutant 
strains showed a higher sensitivity to HU than the matched wild type strain (Plates on left side of 
Figure 3.14 and Figure 3.15). Deletion of HTZ1 has previously been observed to lower resistance 
to HU (278-280). Deletion of SRB2 has been shown to decrease resistance to HU 
(278,279,281,282). However, one study showed that resistance to HU was increased by deletion 
of SRB2 (283). This indicates that the loss of genes involved in transcription can cause S phase 
specific events that cause a hypersensitivity to HU. Double mutants (e.g. cse2∆ mec1∆) were 
also examined for HU hypersensitivity. However, since strains with mec1 mutations are 
exquisitely sensitive to HU, a lower concentration of HU had to be used to study these strains. 
The cse2∆ mec1∆ and srb2∆ mec1∆ strains were more sensitive to 1 mM HU than mec1∆ cells  
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Figure 3.14 The srb2∆ strain carrying the RNAse H plasmid is less sensitive to HU on 
galactose-containing media. WT and single mutant strains were carrying a plasmid where 
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted 
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG 
(complete), SD/MSG (complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal 
(complete) + 100mM HU plates. Plates were incubated at 30°C for two days and scanned.  
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Figure 3.15 The htz1∆ strain carrying the RNAse H plasmid is less sensitive to HU on 
galactose-containing media. WT and single mutant strains were carrying a plasmid where 
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted 
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG 
(complete), SD/MSG (complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal 
(complete) + 100mM HU plates. Plates were incubated at 30°C for two days and scanned.  
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(Figures 3.16, 3.17). This further lends credence to our hypothesis that deletion of Mediator 
subunits causes DNA damage or replication stress. However, it is also possible that the 
transcriptional response to HU is compromised.   
 Since a clear S-phase event is happening in several of the single mutant strains, the 
mechanism causing this HU hypersensitivity was examined. Since the hpr1∆ strain was found to 
harbor an increased level of R-loops, we attempted to examine the effect of R-loops in the single 
and double mutant strains. Yeast strains were transformed with a plasmid that contains the 
RNase H1 (RNH1) gene under the control of the GAL1 promoter. In the presence of galactose, 
strains carrying this plasmid overexpress RNAse H, which degrades RNA:DNA hybrids to 
reduce R-loop levels (63). It has been hypothesized that reduction of sensitivity to HU by RNase 
H indicates R-loop formation (268). Indeed, single and double mutant strains carrying the 
RNAse H plasmid that are normally sensitive to HU were more resistant to HU in the presence 
of galactose. The srb2∆ and htz1∆ single mutant strains displayed this phenotype (Figures 3.14, 
3.15). The srb2∆ mec1∆ strain carrying the RNAse H plasmid also showed a higher resistance to 
1 mM HU in the presence of galactose (Figure 3.17). Interestingly, the cse2∆ mec1∆ strain 
carrying the plasmid showed the opposite effect, a heightened sensitivity to HU when grown on 
media containing galactose (Figure 3.16). This indicates that RNAse H expression was rescuing 
the HU sensitivity of certain strains. However, it was found that the srb2∆ strain without the 
RNAse H plasmid also showed heightened resistance to HU in the presence of galactose (Figure 
3.18). Therefore, the presence of galactose in the media was rescuing the strains’ sensitivities to 
HU. We hypothesize that the transcriptional response to galactose was benefitting certain 
Mediator subunit deletion strains in the response to replication stress induced by HU. Since the 
rescue of sensitivity to HU was at least in part mediated by the presence of galactose in the srb2∆  
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Figure 3.16 The cse2∆ mec1∆ strain carrying the RNAse H plasmid is more sensitive to HU 
on galactose-containing media. HU sensitivity of wild type, single, and double mutant strains 
was assessed. All strains contain the sml1∆ background and were carrying a plasmid where 
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted 
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG 
(complete), SD/MSG (complete) + 1mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal 
(complete) + 1mM HU plates. Plates were incubated at 30°C for two days and scanned.  
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Figure 3.17 The srb2∆ mec1∆ strain carrying the RNAse H plasmid is more resistant to HU 
on galactose-containing media. HU sensitivity of wild type, single, and double mutant strains 
was assessed. All strains contain the sml1∆ background and were carrying a plasmid where 
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted 
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG 
(complete), SD/MSG (complete) + 1mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal 
(complete) + 1mM HU plates. Plates were incubated at 30°C for two days and scanned.  
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Figure 3.18 The srb2∆ strain is less sensitive to HU on galactose-containing media. These 
strains were carrying no plasmid. Overnight cultures were serially diluted (1:10, 1:100, 1:1000, 
and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG (complete), SD/MSG 
(complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 100mM HU 
plates. Plates were grown at 30°C for two days and scanned.  
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strain, it was impossible to analyze whether overexpression of RNAse H had any effect on 
sensitivity to HU. However, it is clear that deletion of certain genes involved in transcriptional 
regulation results in sensitivity to HU.  
 Deletion of a Mediator subunit may cause replication stress, which then activates the 
Mec1 checkpoint and eventually results in cell cycle arrest. In order to investigate cell cycle 
progression, DNA content was analyzed in these strains at different time points of cell cycle 
progression via flow cytometry. Examining the cell cycle profile of yeast strains containing 
deletions of Mediator subunits that genetically interact with MEC1 can provide clues as to 
whether the cell cycle is being arrested. Flow cytometry is used to determine the DNA content in 
individual cells, which indicates which phase of the cell cycle the cell was in when it was 
collected, G1, S, or G2/M phase. Comparing the percentage of cells at each phase of the cell 
cycle between wild type and mutants can be informative as to whether the cells are arresting at a 
certain stage of the cell cycle and can infer if the DDR checkpoint is being activated. First, the 
strains are grown to exponential phase and arrested in G1 phase with yeast mating alpha factor. 
The strains are then released from alpha factor and flow cytometry samples are taken at various 
time points. A cell cycle analysis experiment was performed using a wild type strain and two 
strains containing deletions of Mediator subunits, cse2∆ and srb2∆. In the cse2∆ strain, there 
appears to be a greater percentage of cells in G1 phase at the 20 and 40-minute time points 
(Figure 3.19). This may indicate that the G1/S or intra-S checkpoint is activated. The srb2∆ 
strain appears to be delayed during the G1/S transition, and these cells do not catch up to wild 
type cells during the 120-minute time course (Figure 3.19). One or more checkpoints may be 
activated in this mutant strain. Cell cycle analysis was also performed on double and triple  
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Figure 3.19 Synchronized cell cycle profiles of wild type and single mutant cse2∆ and srb2∆ 
strains. Cells were grown overnight in SD/MSG (complete) media then diluted to OD600 of 0.2 
and grown for two hours at 30°C. They were synchronized with alpha factor for two hours in 
SD/MSG (complete) at 30°C. Alpha factor was removed and cultures were grown at 30°C in 
YPD. Samples were taken every 20 minutes for two hours, fixed, and prepared for flow 
cytometry analysis.  
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mutant strains, such as the srb2∆ mec1∆ sml1∆ strain, but there was no difference in cell cycle 
dynamics between this strain and the srb2∆ or srb2∆ sml1∆ strains (Figure 3.20).  
3.3.2 Synthetic Interactions Between MEC1 and DBF4 or RAD27 in S. cerevisiae 
 
The SGA was performed again in collaboration with Drs. Boone and Brown, this time 
including strains containing conditional mutants and hypomorphs of essential genes. Several 
interesting genes involved in DNA replication and repair, DBF4 and RAD27, were found to 
synthetically interact with MEC1. We discovered these interactions by analyzing the data from 
the SGA screen. “Jackknife” genetic interactions were first removed, where colony size differed 
significantly from its technical replicates (284). The mean and standard deviation of the 
remaining interaction scores were then calculated. The scores outside of the mean plus or minus 
the standard deviation multiplied by two were deemed to be robust interactions. Using this cutoff 
in only the deletion strains, the TEL1 and DST1 interactions were confirmed. Strangely, the 
interaction between MEC1 and the other transcription regulators were not observed with the new 
SGA screen, though the interactions were verified via random spore analysis. When using this 
cutoff, the rad27∆ strain likely formed a synthetic genetic interaction with the mec1∆ sml1∆ 
strain but not the sml1∆ strain. Also, analysis of the SGA results revealed two conditional dbf4 
mutants likely to synthetically interact with MEC1 but not SML1, dbf4-2 and dbf4-ts. Another 
allele, dbf4-1, fell just outside of the cutoff used for the analysis but was within one standard 
deviation from the mean interaction score. Two mutant cdc7 alleles fell within one standard 
deviation from the mean as well, suggesting an interaction between MEC1 and the genes 
encoding DDK. Interestingly, random spore analysis was only able to verify one of the DBF4 
interactions, a mutant containing the dbf4-1 allele (Figure 3.21). This allele has been reported to  
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Figure 3.20 Synchronized cell cycle profiles of srb2∆, srb2∆ sml1∆, and srb2∆ mec1∆ sml1∆ 
strains. Cells were grown overnight in SD/MSG (complete) media then diluted to OD600 of 0.2 
and grown for two hours at 30°C. They were synchronized with alpha factor for two hours in 
SD/MSG (complete) at 30°C. Alpha factor was removed and cultures were grown at 30°C in 
YPD. Samples were taken every 20 minutes for two hours, fixed, and prepared for flow 
cytometry analysis.  
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Figure 3.21 Random spore analysis validates the interaction between MEC1 and DBF4 
using the dbf4-1 allele. Top panel) A haploid MATa strain containing the dbf4-1 allele was 
mated with a mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then 
sporulated and plated onto media that selects for certain MATa mutants and left to germinate. 
Bottom panel) A haploid MATa dbf4-1 strain was mated with a sml1∆ MATα haploid strain, 
sporulated, and plated onto selection media to ensure the synthetic interaction was not between 
DBF4 and SML1. 
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be a P277L mutation (90), which was verified by sequencing. This mutation is predicted to not 
be tolerated by SIFT mutation algorithm (285) and probably damaging by Polyphen 2 mutation 
algorithm (286). Random spore analysis was also used to verify the synthetic interaction between 
MEC1 and RAD27 using the rad27∆ allele. This was a very robust interaction, as can be 
visualized by the extremely small colony size of the rad27∆ mec1∆ strain compared with single 
mutant strains (Figure 3.22). 
Growth rate analysis was performed to quantify the effect of the synthetic genetic 
interactions between MEC1 and DBF4 or RAD27. The dbf4-1 mec1∆ and rad27∆ mec1∆ strains 
grow slowly compared to the single mutants (Figures 3.23, 3.24). This lends quantitative 
evidence to the synthetic interactions between MEC1 and DBF4 or RAD27. The DBF4 and 
RAD27 genes were then cloned into pRS306 integrating plasmids so that after transformation of 
these plasmids into triple mutant strains, the wild type gene would integrate into the endogenous 
locus. We hypothesized that gene add-back would rescue the impaired growth phenotype of the 
triple mutant strains. Indeed, adding the wild type DBF4 gene into the dbf4-1 mec1∆ strain 
rescued the growth rate back to mec1∆ levels (Figure 3.23). Interestingly, add-back of wild type 
RAD27 into the rad27∆ mec1∆ strain only partially rescued the growth phenotype (Figure 3.24). 
This suggests that the impaired growth phenotype of the rad27∆ mec1∆ strain is partly due to 
other mutations distinct from the RAD27 deletion (see Discussion).  
 We hypothesized that mutations in genes involved in DNA replication and repair would 
cause defects during S phase. Mutations in DBF4 could cause aberrant DNA replication 
initiation, and reduced nucleotide pools from HU treatment could exacerbate this problem. 
Deletion of RAD27 causes defects in Okazaki fragment processing, and again, reduction in  
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Figure 3.22 Random spore analysis validates the interaction between MEC1 and RAD27 
using the rad27∆ allele. Top panel) A haploid MATa rad27∆ strain was mated with a mec1∆ 
sml1∆ MATα haploid strain. The heterozygous diploid strain was then sporulated and plated onto 
media that selects for certain MATa mutants and left to germinate. Bottom panel) A haploid 
MATa rad27∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto 
selection media to ensure the synthetic interaction was not between RAD27 and SML1. 
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Figure 3.23 Growth rate of single and double mutants in the sml1∆ background verifies the 
synthetic genetic interaction between DBF4 and MEC1. Cells were brought to 0.2 OD600 in 
SD/MSG (complete) media and grown at 23°C. OD600 was measured via spectrometry at regular 
intervals to determine approximate cell density. Three independent experiments were performed, 
and a representative experiment is shown. 
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Figure 3.24 Growth rate of single and double mutants in the sml1∆ background verifies the 
synthetic genetic interaction between RAD27 and MEC1. Cells were brought to 0.2 OD600 in 
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular 
intervals to determine approximate cell density. Three independent experiments were performed, 
and a representative experiment is shown. 
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nucleotide pools would probably aggravate this defect. Therefore, we hypothesized that 
mutations in DBF4 or deletion of RAD27 would cause a hypersensitivity to HU in wild type and 
mec1∆ backgrounds. Interestingly, wild type levels of sensitivity to HU were found in the 
rad27∆ strain and dbf4 mutant strains (Figure 3.25). It was then hypothesized that Mec1 may 
provide a protective effect in response to HU when DBF4 or RAD27 was mutated. However, 
there was no change in sensitivity to HU in the rad27∆ mec1∆ or dbf4-1 mec1∆ strains compared 
to the mec1∆ strain (Figures 3.26, 3.27).  
 We hypothesized that mutations in genes critical for DNA replication would cause 
defects in cell cycle progression. A cell cycle analysis in WT and dbf4 mutant strains was 
performed at a permissive temperature. A previous study showed that a dbf4 mutant strain arrests 
in S phase when grown at the restrictive temperature of 37°C (287). Our experiment shows a cell 
cycle delay in G1 and early S phase in multiple dbf4 mutant strains including the dbf4-1 strain 
(Figure 3.28).  
3.3.3 Synthetic Interactions are Recapitulated in Human Cancer Cells 
 
 It was next investigated whether synthetic interactions between MEC1 and genes 
involved in transcription regulation or DNA replication were conserved in human cancer cells. 
The tumor suppressor protein p53 could also be investigated as to whether it was involved in the 
interactions. This type of analysis can only be conducted using human cells, since there is no 
known ortholog of TP53 in S. cerevisiae (288). Non-small cell lung cancer (NSCLC) cell lines 
were chosen primarily because cisplatin is often used in the treatment of NSCLC, and ATR 
inhibitors have been found to potentiate the effects of cisplatin in vitro and in vivo (289-293).  
Importantly, TP53 mutations are present in approximately half of all NSCLC patients (294-298). 
FEN1 is also often over expressed in NSCLC (263) and ATM is mutated in approximately 7% of  
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Figure 3.25 dbf4 mutations or rad27∆ do not change HU resistance. HU sensitivity was 
assessed in wild type and single mutant strains. Overnight cultures were serially diluted (1:10, 
1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG (complete), 
SD/MSG (complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 
100mM HU plates. Plates were grown at 30°C for two days and scanned.  
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Figure 3.26 rad27∆ does not affect HU resistance in the mec1∆ background. HU sensitivity 
was assessed in wild type, single, and double mutant strains. All strains contain the sml1∆ 
background. Overnight cultures were serially diluted (1:10, 1:100, 1:1000, and 1:10000) and 5 µl 
of each dilution was spotted onto SD/MSG (complete), SD/MSG (complete) + 1mM HU, 
SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 1mM HU plates. Plates were grown at 
30°C for two days and scanned. 
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Figure 3.27 The dbf4-1 mutation does not affect HU resistance in the mec1∆ background. 
HU sensitivity was assessed in wild type, single, and double mutant strains. All strains contain 
the sml1∆ background. Overnight cultures were serially diluted (1:10, 1:100, 1:1000, and 
1:10000) and 5 µl of each dilution was spotted onto SD/MSG (complete), SD/MSG (complete) + 
1mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 1mM HU plates. Plates 
were grown at 30°C for two days and scanned.  
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Figure 3.28 Synchronized cell cycle profiles of wild type, and single mutant dbf4 strains. 
Cells were grown overnight in rich media (YPD) then diluted to OD600 of 0.2 and grown for two 
hours at 23°C in YPD. They were synchronized with alpha factor for two hours in YPD at 23°C. 
Alpha factor was removed and cultures were grown at 23°C in YPD. Samples were taken every 
30 minutes for two hours, fixed, and prepared for flow cytometry analysis.  
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lung adenocarcinomas (299). Since these genes form synthetic interactions with ATR, this could 
mean that ATR inhibitors are more effective in NSCLC cells. The work was done primarily in 
three NSCLC cell lines, large cell lung carcinoma NCI-H460, non-small cell lung carcinoma 
NCI-H1299, and lung adenocarcinoma A549. The H460 and A549 cell lines contain wild type 
p53 while the H1299 cell line is null for p53 expression (300). Preliminary data indicated that 
shRNA knockdown of FEN1, DBF4, MED9, and to a lesser extent MED20 (the human orthologs 
of the Mediator subunits and DNA replication genes that were found to synthetically interact 
with MEC1) sensitized H460 cells to a small-molecule inhibitor of ATR, VE-822 (Figure 3.29). 
This suggested that orthologs of yeast genes that interact with MEC1 interact with ATR in a 
human NSCLC cell line. However, there was poor knockdown of the gene targets possibly 
because of toxicity associated with loss of these gene products. Deletion of FEN1 (301) or CDC7 
(302) has been shown to cause early embryonic lethality in mice, and many subunits of the 
Mediator complex are also essential for embryonic development in mice (303-306). We 
hypothesized that long-term knockdown of these genes is toxic, so the cells that had efficient 
knockdown died and only cells with less efficient knockdown remained.  
 To overcome this effect, we opted for knockdown using transient siRNA that were 
posited to be less toxic. A pooled set of four different siRNA (GE Dharmacon) were used to 
knockdown expression of one of four genes, MED9 (hCSE2), MED20 (hSRB2), FEN1 
(hRAD27), and DBF4 along with a non-targeting scrambled pool of siRNAs as a control in two 
human NSCLC cell lines. The levels of mRNA of the targeted genes were quantified and 
normalized to the housekeeping gene, GAPDH. In H460 cells there was 96% reduction of levels 
of MED20, 93% reduction of levels of DBF4, and 87% reduction of levels of FEN1. In H1299 
cells, levels of MED20 were reduced by 85%, DBF4 by 72%, and FEN1 by 77%. Western  
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Figure 3.29 Knockdown of MED9, MED20, DBF4, or FEN1 sensitizes H460 cells to ATRi. 
H460 cells treated with shRNA were treated for four hours with indicated doses of VE-822 
(ATRi) in serum-free media. Media was replaced with complete media and cells were left to 
grow until colonies formed with more than 50 cells. Cells were then stained with crystal violet 
and colonies with more than 50 cells were counted. Cells treated with shRNA against the four 
genes were compared with cells treated with scrambled shRNA. This data is based on a single 
experiment with three replicates. Error bars are based on standard deviation between the three 
replicates.  
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blotting was also performed on MED9, DBF4, and FEN1 in H1299 cells and found reduced 
protein levels of each after knockdown with their respective siRNA (Figure 3.30). The 
knockdown cells were treated with an ATR inhibitor (ATRi), VE-822. This time, there was no 
sensitization of the knockdown cells to ATRi in the H460 cell line (Figure 3.31). The identical 
experiment was performed using the H1299 cell line and the original results from the H460 
shRNA knockdown experiments were recapitulated. After knockdown of MED9, MED20, FEN1, 
or DBF4, H1299 cells were sensitized to the ATRi (Figure 3.30).  
3.3.4 Synergistic Effects of ATR and DDK Inhibitors in p53 Null Cells 
 
 We hypothesized that chemical inhibition of MED9, MED20, DBF4, or FEN1 using 
small-molecule inhibitors would show the same effect as genetic knockdown. An inhibitor exists 
of CDC7 (the catalytic subunit of DDK), XL-413 (DDKi). As noted before, this drug appears to 
be highly specific for DDK (253). We found that phosphorylation of MCM2 at serine 53, a target 
of DDK, was decreased after treatment with DDKi (Figure 3.32). This indicates that DDKi was 
inhibiting the catalytic activity of DDK. H1299 cells were treated with escalating doses of DDKi 
with or without a dose of ATRi that prevented approximately 50% of colony formation as a 
single treatment. ATRi treatment sensitized H1299 cells to DDK inhibition by ~10-fold (Figure 
3.33). Based on these data, small-molecule inhibitors of ATR and DBF4 may be synergistic in 
the H1299 cell line. H1299, A549, or H460 cells were treated with single drugs and different 
doses but an identical ratio of the two drugs using a standard colony assay. CompuSyn (272) was 
then used to analyze the data and create combination index values. The dose of each single drug 
required to prevent 90% of colony formation was plotted on the axes and a line was drawn 
between them. The combination index values were then used to calculate the dose of the DDKi 
required to prevent 90% of colony formation in combination with the indicated dose of ATRi. If  
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Figure 3.30 Knockdown of MED9, MED20, DBF4, or FEN1 with siRNA sensitizes H1299 
cells to ATRi. H1299 cells treated with siRNA were treated for four hours with indicated doses 
of VE-822 (ATRi) in serum-free media. Media was replaced with complete media and cells were 
left to grow until colonies formed with more than 50 cells. Cells were then stained with crystal 
violet and colonies with more than 50 cells were counted. Cells treated with siRNA against the 
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four genes were compared with cells treated with non-targeting siRNA. The data is the average 
of three independent experiments each with three replicates. Error bars are calculated based on 
standard error between the three experiments. Samples for protein analysis were collected on the 
same day cells were seeded, which was the day before treatment. Western blotting validated that 
siRNA against MED9, DBF4, or FEN1 decreased protein levels. 
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Figure 3.31 Knockdown of MED9, MED20, DBF4, or FEN1 with siRNA does not sensitize 
H460 cells to ATRi. H460 cells treated with siRNA were treated for four hours with indicated 
doses of VE-822 (ATRi) in serum-free media. Media was replaced with complete media and 
cells were left to grow until colonies formed with more than 50 cells. Cells were then stained 
with crystal violet and colonies with more than 50 cells were counted. Cells treated with siRNA 
against the four genes were compared with cells treated with non-targeting siRNA. This data is 
based on a single experiment with three replicates. Error bars are based on standard deviation 
between the three replicates. 
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Figure 3.32 Phospho-MCM2 is decreased after treatment with DDKi. H460 (wild type and 
p53 knockout) cells were treated for 24 hours with 125 nM VE-822 (ATRi) or 35 µM XL-413 
(DDKi) as single drugs and in combination. Protein was harvested 24 hours after treatment and 
western blotting was used to examine total MCM2, phospho-MCM2, and tubulin.  
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Figure 3.33 Treatment with ATRi sensitizes H1299 cells to DDKi. H1299 cells were treated 
for 24 hours with indicated doses of XL-413 (DDKi) with or without 150 nM VE-822 (ATRi), in 
complete media. Media was replaced and cells were left to grow until colonies formed with more 
than 50 cells. Cells were then stained with crystal violet and colonies with more than 50 cells 
were counted. This data is based on a single experiment with three replicates. Error bars are 
based on standard deviation between the three replicates.  
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this value is above the line, the two drugs are antagonistic. If this value is along the line, the 
drugs display an additive effect. If this value is below the line, the two drugs are synergistic. 
Using this analysis, the ATRi and DDKi were found to be highly synergistic in the H1299 cell 
line. Interestingly, the two drugs showed an additive or slightly antagonistic relationship in the 
H460 and A549 cell lines (Figure 3.34). 
 Since H1299 cells do not express p53 and H460 and A549 cells express wild type p53, 
we hypothesized that p53 has an effect on the functional interaction between ATR and DBF4. If 
this were true, A549 or H460 cells where p53 is eliminated would be sensitized to ATR 
inhibition by a DDK inhibitor. Exon 6 of TP53 was disrupted using the CRISPR/cas9 system in 
the H460 and A549 cell lines that normally contain wild type TP53 to create p53 knockout 
models (H460 p53∆ and A549 p53∆). Synergy analysis was performed using these cell lines, and 
ATRi and DDKi were highly synergistic in the A549 p53∆ and H460 p53∆ cells (Figure 3.34). 
This strongly suggests that synergy between ATRi and DDKi is dependent on the absence of 
p53. CompuSyn was also used to calculate the combination index (CI) values obtained at 
different doses of ATRi and DDKi. A CI value greater than one indicates antagonism, less than 
one indicates synergy, and approximately one indicates an additive effect. We plotted the CI 
value as a function of the doses of the two drugs. There is a trend towards more robust synergy at 
the higher doses in the H1299 and H460 p53∆ cells. There is a slight trend towards lower 
synergy in the A549 p53∆ cells at higher doses (Figure 3.35).  
 Interestingly, data from the synergy experiments showed that p53∆ cells were more 
resistant to ATRi than their matched isogenic wild type counterparts in both A549 and H460 cell 
lines (Figure 3.36). This is in disagreement with most findings thus far (see Discussion). A549 
p53∆ cells were also observed to be more resistant to DDKi than A549 wild type cells. H460  
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Figure 3.34 ATRi and DDKi synergize in cells without expression of p53. H1299, H460 (wild 
type and p53 knockout) and A549 (wild type and p53 knockout) cells were treated for 24 hours 
with varying doses of VE-822 (ATRi), XL-413 (DDKi) or ATRi and DDKi at a constant ratio in 
complete media. Media was replaced and cells were left to grow until colonies formed with more 
than 50 cells. Cells were then stained with crystal violet and colonies with more than 50 cells 
were counted. The percentage of cells surviving treatment was calculated compared to vehicle 
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treated control and converted to fraction affected. CompuSyn was used for data analysis. The 
data is the average of three independent experiments each with three replicates. The dose 
required for prevention of 90% of colony formation for ATRi is plotted on the x-axis and the 
same value for DDKi is plotted on the y-axis. A line is then drawn between the points. The dose 
of DDKi required to prevent 90% colony formation along with the indicated dose of ATRi was 
calculated. If these points are below the line, there is a synergistic effect. If these points are along 
the line, there is an additive effect between the drugs. If the points are above the line, the drugs 
are antagonistic. Error bars are calculated based on standard error between three experiments. 
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Figure 3.35 Synergy patterns differ with different doses in different cell lines. The 
percentage of cells surviving treatment was calculated compared to vehicle treated control and 
converted to fraction affected. CompuSyn was used to calculate combination index (CI) values 
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using the data from Figure 3.34. A CI value over one, approximately one, or less than one 
indicates that the two drugs are antagonistic, additive, or synergistic respectively.  
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Figure 3.36 p53 knockout cells are more resistant to ATRi. H460 (wild type and p53 
knockout) and A549 (wild type and p53 knockout) cells were treated for 24 hours with varying 
doses of VE-822 (ATRi) in complete media. Media was replaced and cells were left to grow 
until colonies formed with more than 50 cells. Cells were then stained with crystal violet and 
colonies with more than 50 cells were counted. The data is the average of three independent 
experiments each with three replicates. Error bars are calculated based on standard error between 
the three experiments. 
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p53∆ were only marginally more resistant to DDKi at the highest dose, but there was no 
difference at the lower doses (Figure 3.37). In both cell lines, p53∆ cells displayed similar 
sensitivities to the ATRi plus DDKi dual treatment (Figure 3.38). This indicates that synergy was 
achieved in p53∆ cells because DDKi treatment overcame the resistance to ATRi. In A549 p53∆ 
cells it could also be that ATRi treatment overcame the resistance to DDKi (see Discussion).   
 We hypothesized that combination treatment of ATRi and DDKi was inducing p53-
independent apoptosis in NSCLC cell lines. In order to investigate, H460 WT and H460 p53∆ 
were treated with ATRi and DDKi alone or in combination. The cells were treated with doses of 
ATRi and DDKi that prevent approximately 50% of colony formation. 24 hours after treatment, 
protein was harvested and probed with a PARP1 antibody. Cleaved PARP1 is an established 
marker for apoptosis (307-309). We found a greater amount of cleaved PARP1 in cells treated 
with the combination treatment than in single drug treated cells or vehicle treated cells in both 
WT and p53∆ H460 cells (Figure 3.39). This indicates that apoptosis is a significant mechanism 
induced by ATRi and DDKi dual treatment in H460 cells even in cells lacking p53 expression.  
3.4 Discussion  
 
 We discovered that adding back the wild type RAD27 into the rad27∆ mec1∆ mutant 
strain did not completely rescue the observed growth defect (see Figure 3.24). It was perplexing 
as to why the gene add-back did not completely rescue the impaired growth phenotype like the 
wild type DBF4 gene rescued growth of the dbf4-1 mec1∆ strain. It is also interesting that 
RAD27 shows synthetic genetic interactions with a multitude of different genes. When applying 
a stringent cutoff to data from a SGA screen performed by the Boone lab, there were 330 
negative genetic interactions with a rad27∆ allele (204). Perhaps there are secondary mutations 
in the rad27∆ strain that are the culprit behind some of these synthetic genetic interactions. Since 
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Figure 3.37 A549 p53 knockout cells are more resistant to DDKi. H460 (wild type and p53 
knockout) and A549 (wild type and p53 knockout) cells were treated for 24 hours with varying 
doses of XL-413 (DDKi) in complete media. Media was replaced and cells were left to grow 
until colonies formed with more than 50 cells. Cells were then stained with crystal violet and 
colonies with more than 50 cells were counted. The data is the average of three independent 
experiments each with three replicates. Error bars are calculated based on standard error between 
the three experiments. 
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Figure 3.38 A549 and H460 p53 knockout cells show similar sensitivities to ATRi and DDKi 
dual treatment. H460 (wild type and p53 knockout) and A549 (wild type and p53 knockout) 
cells were treated for 24 hours with varying doses of VE-822 (ATRi) and XL-413 (DDKi) at a 
constant ratio of 1:280 ATRi:DDKi in complete media. Media was replaced and cells were left to 
grow until colonies formed with more than 50 cells. Cells were then stained with crystal violet 
and colonies with more than 50 cells were counted. The x-axis is the total dose of ATRi plus 
DDKi. The data is the average of three independent experiments each with three replicates. Error 
bars are calculated based on standard error between the three experiments. 
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Figure 3.39 ATRi, DDKi, and dual treatment induces apoptosis in H460 cells. H460 (wild 
type and p53 knockout) cells were treated for 24 hours with 125 nM VE-822 (ATRi) and 35 µM 
XL-413 (DDKi) as single drugs and in combination. Protein was harvested 24 hours after 
treatment and western blotting was used to examine PARP1 and tubulin.  
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RAD27 is integral in maintaining genomic integrity (276,310-313), deletion of RAD27 could be 
causing an increased mutational load in the rad27∆ strain that is perhaps causing some of the 
observed synthetic genetic interactions. Alternatively, RAD27 may be an essential gene in yeast, 
as is the mouse orthologue (301). Similar to mutation of SML1 rescuing viability of the mec1∆ 
strain, mutation of a separate unknown gene could rescue viability of rad27∆ strains. Perhaps 
this unknown gene is causing some of the observed synthetic interactions.  
Several of the synthetic genetic interactions that were uncovered in yeast have been 
confirmed in recent studies. A recent genome wide SGA screen by the Boone laboratory 
uncovered synthetic genetic interactions between the temperature sensitive mec1-4ts allele and 
four dbf4 mutant alleles. They also uncovered interactions between the mec1 mutant and two 
cdc7 mutant alleles (204). Several studies examined these interactions using human cells. A 
screen found that siRNA against CDC7 sensitized U2OS cells to ATRi (314). Another screen 
used siRNA against a panel of genes to look at which siRNA sensitized two cell lines to ATRi. 
Interestingly, they found that knockdown of a gene involved in translesion synthesis, RAD18, 
sensitized both cell lines to ATRi. However, they did not find siRNA against CDC7 or FEN1 to 
sensitize the cell lines to ATRi (186).  
 Work detailed in Chapter 2 showed that deletion of genes involved in transcription 
regulation confers a loss of fitness in terms of cell cycle progression (see Figure 3.19). In the 
cse2∆ strain, the G1/S or intra-S checkpoints may be activated. A more robust effect was 
observed in the srb2∆ strain, indicating a more robust G1/S or intra-S checkpoint may be 
activated in the srb2∆ strain (Figure 3.19). A difference in terms of cell cycle progression was 
not observed when comparing the srb2∆ and srb2∆ mec1∆ strains (See Figure 3.20). We 
hypothesized that the cell cycle arrest in single mutant strains occurs because of DNA damage 
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from deletion of a Mediator subunit causing a Mec1-dependent cell cycle arrest. Loss of MEC1 
in the srb2∆ deletion strain probably results in loss of cell cycle arrest, which should lead to a 
faster cell cycle progression. However, the slow growth of the double mutant strain may be 
caused by DNA damage interfering with DNA replication. Strains lacking certain genes involved 
in transcriptional regulation were observed to be hypersensitive to HU. This hypersensitivity 
may be due to DNA damage/replication stress that may be activating the Mec1 checkpoint.  
 We further found that dbf4 or rad27 mutants were not hypersensitive to HU, suggesting 
that these mutants are not defective in S phase. This was surprising, since both proteins are 
integral in DNA replication. We hypothesize that there are redundant pathways that can 
compensate for defective DBF4 or RAD27. There was an S phase arrest detected in dbf4 mutant 
strains (Figure 3.28). These strains may be displaying a defect in DNA replication initiation, 
which is slowing down progression through S phase. However, this defect is not robust enough 
to cause a decrease in viability when the cells are challenged with replication stress via HU. 
 Knockdown of the human orthologs of genes that synthetically interact with MEC1 in 
yeast sensitize a NSCLC cell line to ATRi. Therefore, the genetic interactions between MEC1 
and genes encoding Mediator subunits, DBF4, and FEN1 appear be conserved between yeast and 
a human NSCLC cell line. This indicates that orthologs of yeast genes that interact with MEC1 
also interact with ATR in human NSCLC cells. There was an additive or slightly antagonistic 
effect between DDKi and ATRi in the p53 wild type H460 and A549 cell lines. However, 
synergy was observed between the two drugs in H460 p53∆ and A549 p53∆ cells. Synergy was 
also observed between the drugs in the p53 null H1299 cell line. This strongly suggests a 
synthetic sick phenotype between DDK and ATR, which is dependent on the absence of p53. 
Perhaps the p53 checkpoint pathway was compensating for loss of the ATR checkpoint pathway. 
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A combination of targeted ATRi and DDKi treatments would potentially have fewer off-target 
effects and be more effective than combination of an ATR inhibitor plus a cytotoxic 
chemotherapy, such as is currently being tested in clinical trials.  
 These genetic interaction studies show that Mec1/ATR is functionally important when 
Mediator subunits or proteins involved in DNA replication/repair are defective or inhibited. 
Downregulation of a Mediator subunit, DBF4, or FEN1 could have caused increased levels of 
DNA damage that required ATR/MEC1 to delay the cell cycle in order for the damage to be 
repaired. However, there was no evidence that Mediator subunit deletion caused DSBs or 
checkpoint activation in yeast, but these techniques may not be sensitive enough to detect such 
changes. Alternatively, ATR/Mec1 inhibition could be causing transcriptional defects that 
require transcriptional regulators like Mediator subunits to compensate for in order to avoid a 
loss in fitness. ATR/Mec1 inhibition may also be causing defects in the DDR that the DNA 
repair functions of RAD27/FEN1 could be compensating for.  
 In the case of the DBF4 interaction, ATR/Mec1 loss/inhibition may be causing DDR 
defects that could require DBF4 for compensation. These experiments did not directly probe the 
mechanism behind the genetic interactions between MEC1 and DBF4. However, earlier research 
has provided clues as to the reason behind the synthetic interactions. In S. cerevisiae, Mec1 
phosphorylates certain residues on Mcm4 and Mcm6 that primes the helicase complex subunits 
for phosphorylation by DDK (315). In our system, this could mean that Mec1 phosphorylation of 
the MCM2-7 complex could be compensating for loss of MCM2-7 phosphorylation by DDK. If 
Mec1 is not being expressed and DDK is defective, there may be a significant loss of 
phosphorylation of the MCM helicase, which would decrease origin firing, stall replication forks, 
and ultimately result in a loss in fitness. In line with this hypothesis, it has been reported that the 
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dbf4-1 mutant (the allele that synthetically interacts with mec1∆) has impaired interaction with 
Mcm2 and Orc2 at a semipermissive temperature. However, the mutant dbf4 can still interact 
with Rad53 (76). This indicates that the DBF4 function in regulation of origin firing may be 
involved in the interaction with MEC1, not the ability of DBF4 to be activated by the Mec1 
checkpoint.  
 Another possibility is that the DDR checkpoint is impaired because of reduced 
phosphorylation of CHK1. CDC7 is known to catalyze phosphorylation of Claspin in 
mammalian cells, which is required for CHK1 phosphorylation (92). CHK1 is also a well-known 
target of ATR phosphorylation (15), so it is also possible that DDK and ATR can compensate for 
one another’s loss by phosphorylating CHK1. Inhibition of both DDK and ATR could be causing 
a significant loss of CHK1 phosphorylation, which could cause a defect in the DDR and cause 
the loss in fitness that was observed. In agreement with this hypothesis is a study finding that 
CHK1 and ATR inhibitors are synergistic. However, this also may have to do with the regulation 
of origin firing because inhibition of CDK prevented the synergy between the two inhibitors 
(316). Therefore, decreases in MCM and CHK1 phosphorylation caused by inhibition of 
ATR/Mec1 and DDK may be altering origin firing dynamics and causing the observed synergy 
and synthetic sickness.  
 Several lines of evidence indicate a negative synthetic genetic interaction between ATR 
and TP53. Combination of homozygous null TP53 expression and hypomorphic expression of 
ATR in a mouse model potentiated the phenotype of the hypomorphic ATR mouse model (23). 
Two studies showed p53-deficient cells to be more sensitive to ATR inhibitors than p53-
proficient cells (38,184). Also, ATR downregulation sensitized p53 deficient cells to DNA 
damage to a greater extent than p53 proficient cells (317-319). Counter to this information, we 
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found that p53∆ cell lines were more resistant to single agent ATRi than matched isogenic wild 
type cell lines in both A549 and H460 cells (see Figure 3.36). Genes involved in 
chemoresistance were more highly expressed in lung tumors with high expression of CDC7, 
which indicates that CDC7 may play a role in resistance to ATR inhibition (245).  
 The data shows synergy between ATRi and DDKi in p53 null cells and an additive or 
antagonistic effect between the two drugs in the matched isogenic cells expressing wild type p53 
(see Figure 3.34). This falls in line with other research showing greater sensitization to other 
drugs by ATR inhibitors in p53-deficient cells. An ATR inhibitor, AZD7762 enhanced radio-
sensitivity of several different cancer cell lines, and radio-sensitivity was enhanced to a greater 
extent in p53 deficient cells (320). In another study, Myc-driven oncogenic stress caused ATR 
and CHK1 inhibitors to be synthetic lethal. This effect was greater in p53-deficient cells (321). 
Knockdown of p53 by siRNA or degradation of p53 by expression of human papillomavirus E6 
protein enhanced the synergy between an ATR inhibitor, VE-821, and cisplatin (27). VE-822 
also synergized more strongly with cisplatin in p53-deficient cell lines (292).  
 Mechanistically, p53 acts post-transcriptionally and post-translationally to reduce CDC7 
expression to achieve cell cycle arrest. When CDC7 is overexpressed, which often occurs in 
cancer cells, it can act in a feedback loop to reduce p53 levels (322). In our p53 wild type cell 
lines, p53 may have reduced expression from the actions of DDK. In addition to the role of p53 
in apoptosis pathways, it has been realized that p53 also plays a role in cell survival (323). DDK 
inhibition could be increasing p53 expression, which could be acting in a pro-survival pathway 
to initiate cell cycle arrest when ATR is also being inhibited.  
 Similarly, A549 p53∆ cells are more resistant to DDKi than matched isogenic A549 wild 
type cells. In the presence of ATR, p53 may switch from a pro-survival to a pro-apoptotic 
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pathway. When only DDK is inhibited, p53 is involved in an ATR-dependent pro-apoptotic 
pathway. When DDK is inhibited in p53∆ cells, the p53-dependent pro-apoptotic pathway is 
missing, which results in resistance to the DDKi. Intriguingly, there was not a clear difference in 
resistance between H460 and H460 p53∆ matched isogenic cells. One difference between H460 
and A549 cell lines is that A549 cells contain amplified MYC (300). Perhaps MYC 
overexpression and p53 expression are essential for the pro-apoptotic pathway in response to 
DDKi. Knockdown of ATR with RNA interference increased cell viability in response to DDKi, 
indicating that ATR is necessary for cell death pathways in response to DDK inhibition (245). 
This was observed in HeLa cells, which contain wild type but reduced expression of p53 from 
the expression of the human papillomavirus E6 protein (324), and HCC1954 cell lines that 
contain a point mutation in p53 (325). This indicates that cells expressing p53, even if p53 is 
mutant or at reduced levels, can use ATR as a resistance mechanism to DDKi treatment. Perhaps 
this pathway depends on expression of p53 in order to enable the pro-survival ATR pathway.  
 These results also indicate that wild type and p53∆ matched isogenic cells show 
approximately the same pattern in sensitivity to dual ATRi and DDKi treatment (Figure 3.38). 
However, the synergy observed between the two drugs in the p53∆ cell lines seemed to occur 
because DDKi treatment overcame resistance to ATRi. Inhibiting DDK and ATR may prevent 
late origin firing, which stalls replication forks and causes conflicts between the replication and 
transcription machineries. Cells expressing p53 can deal with this stress by utilizing a p53-
dependent pro-survival pathway. In p53∆ cells, this stress cannot be dealt with and it ultimately 
leads to p53-independent apoptosis. This is substantiated by our PARP cleavage data showing 
p53-independent apoptosis in H460 cells after treatment with ATRi and DDKi (Figure 3.39). In 
A549 cells, p53∆ cells are resistant to both ATRi and DDKi, but treatment with either inhibitor 
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overcomes the resistance to the other. The same mechanism may also be occurring as in H460 
cells, but another possibility is that ATR is involved in a pro-survival pathway when p53 is not 
expressed in A549 cells. So, inhibiting ATR halts this pathway and overcomes the resistance to 
DDKi.  
 In conclusion, the presence of synthetic genetic interactions was clearly demonstrated 
between genes involved in transcriptional regulation or DNA replication and MEC1/ATR in S. 
cerevisiae and human NSCLC cell lines. In yeast, there was a hypersensitization of Mediator 
subunit deletion strains to HU both in a wild type and mec1∆ background. A cell cycle delay was 
observed in Mediator subunit or dbf4 single mutant yeast strains. Knockdown of Mediator 
subunits, DBF4, or FEN1 sensitizes human p53 null NSCLC cells to ATR inhibition. Finally, 
there was an additive or antagonistic effect between ATRi and DDKi in NSCLC cells containing 
wild type p53. Synergy was observed between the two drugs in matched isogenic cells 
engineered to prevent expression of p53, and this seems to occur because DDKi overcame the 
resistance to ATRi detected in p53∆ cells.  
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CHAPTER 4 – CONCLUSIONS 
 
 In conclusion, these data highlight novel functions of Mec1 and Dbf4 in the S. cerevisiae 
meiotic recombination checkpoint and functional interactions between MEC1/ATR and DBF4, 
RAD27/FEN1, or Mediator subunit genes in yeast and human NSCLC cells. We found novel 
functions of Mec1 and Dbf4 in preventing SIC1∆PHA–induced DNA rereplication when the 
meiotic recombination checkpoint is induced by deletion of DMC1 (Chapter 2). We also found 
novel functional interactions between MEC1 and genes involved in transcription regulation and 
genes involved in DNA replication in S. cerevisiae. We recapitulated these results using human 
orthologs of these genes in NSCLC cells. We further found that small-molecule inhibitors of 
ATR and DDK were synergistic in p53 null NSCLC cells. Synergy was not observed in matched 
isogenic cells expressing wild type p53 (Chapter 3). Importantly, these data demonstrate that 
synthetic interactions discovered in yeast can predict synergy between two targeted therapies in 
preventing growth of certain cancer cells. The simplicity of discovering novel synthetic genetic 
interactions using S. cerevisiae makes the model organism a useful tool in searching for genetic 
vulnerabilities in cancer cells. These studies support the many findings in the literature that ATR 
and DDK are effective targets to inhibit in cancer cells. 
 These novel functions and functional interactions of ATR/MEC1 are significant and 
contribute to a greater understanding of how ATR inhibitors function as a cancer therapy. Our 
data suggests that reduced expression of FEN1, DBF4, or certain Mediator subunits heightens 
sensitivity to ATRi in NSCLC cell lines. This could mean that lowered expression of these genes 
in NSCLC cells could be used as a biomarker for ATRi use. The data indicating a higher 
resistance to ATRi in matched isogenic p53∆ cells was unexpected. Expression of p53 could be 
used as a biomarker for ATRi use if this finding is substantiated with further evidence. These 
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studies also suggest that DDK inhibitors could be used to overcome the resistance to ATR 
inhibitors in p53∆ cells. 
 Both projects leave many questions to be answered. The major question coming from the 
meiosis project was the identity of the kinase responsible for catalyzing phosphorylation of Dbf4 
and presumably Sld3 to prevent DNA rereplication when the meiotic recombination checkpoint 
is activated. Other kinases could be examined in our system by mutating kinases likely to be 
responsible for these phosphorylation events in the SIC1∆PHA dmc1∆ background. If mutation of 
the kinase results in DNA rereplication when sporulation is induced, then the kinase could be 
looked at further. It would be useful to examine Dbf4 and Sld3 phosphorylation using a strain 
with a mutant kinase and comparing it with a WT strain after induction of meiosis. Future studies 
could also delve into whether it is the function of Dbf4, Sld3, or both proteins in preventing 
DNA rereplication. We only studied a strain containing phosphorylation site mutants of both 
genes at once. We hypothesize that both would be involved and that mutation of DBF4 alone or 
SLD3 alone would both cause a return to the rereplication phenotype in SIC1∆PHA dmc1∆ cells. 
More research could also be performed to discover if these proteins are involved in prevention of 
DNA rereplication during meiosis in human cells.  
 There is still much work to be done for the synthetic interaction project. It will be 
important to examine the mechanism by which ATR and DDK inhibition prevents colony 
formation. PARP cleavage data suggests that ATRi and DDKi dual treatment induces apoptosis 
in H460 cells, but this may not be the major mechanism, especially in other cell lines. It will be 
essential to verify apoptosis using other techniques, such as flow cytometry. Cell cycle analysis 
would be useful, which could indicate if the inhibitors induce cell cycle arrest. A translational 
study could include treatment of a p53 null NSCLC xenograft mouse model with ATRi and 
119 
		
DDKi as single treatments and comparing with dual treatment. Future studies could also include 
testing structurally different ATR and DDK inhibitors to ensure that the mechanism of synergy is 
not due to off-target effects. It will be beneficial to more thoroughly study the functional 
interactions of ATR and Mediator subunits or FEN1 in cancer cells. We hypothesize that small 
molecule inhibitors of FEN1 or Mediator subunits will synergize with ATR inhibitors. When 
FEN1 inhibitors are more thoroughly tested and when Mediator subunit inhibitors become 
available, they could be tested for synergy with ATRi. These approaches could provide strategies 
to enhance the effectiveness of ATRi-based cancer therapy.  
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ABSTRACT 
 
FUNCTIONS OF ATR/MEC1 IN MEIOSIS AND THE CELL CYCLE  
by 
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Major: Cancer Biology 
Degree: Doctor of Philosophy  
Mec1 is a protein kinase in S. cerevisiae that is critical for the DNA damage checkpoint 
response, and is the yeast orthologue of the human ATR protein. Cancer cells rely on ATR to 
arrest the cell cycle and allow sufficient time to repair DNA damage before proceeding through 
the cell cycle, and ATR inhibitors have been developed as possible anti-cancer agents. DBF4 is 
the regulatory subunit of DBF4-dependent kinase (DDK) that regulates initiation of DNA 
replication and is overexpressed in a number of different cancer types. To better understand ATR 
and DBF4 function, we took advantage of yeast genetics to examine the role of Mec1 and Dbf4 
in prevention of DNA rereplication during meiosis. We found that Dbf4 phosphorylation sites 
and Mec1 were essential for prevention of DNA rereplication when the meiotic recombination 
checkpoint was activated by deletion of DMC1. We further found evidence that Dbf4 was 
phosphorylated by a kinase other than the canonical Rad53 or Mek1 protein kinases.  
We also examined genes that synthetically interact with MEC1 in order to better 
understand the function of Mec1 during the normal cell cycle. Synthetic genetic interactions 
occur when fitness is not affected by a single mutation of one of two genes, but when both of the 
two genes are mutated a significant loss in fitness occurs. Among the many genes identified to 
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synthetically interact with MEC1, many are involved in mRNA transcription, including several 
subunits of the Mediator complex. We also found genes involved in DNA replication to 
synthetically interact with MEC1, such as RAD27 and DBF4. We assessed whether these 
synthetic interactions exist in human non-small cell lung cancer (NSCLC) cell lines. We 
discovered that inhibitors of ATR and DDK act synergistically in p53 null cell lines but not in 
p53 wild type cell lines. This data suggests a synthetic interaction between ATR and genes 
involved in transcriptional regulation or DNA replication in NSCLC cells that is dependent on 
the absence of p53. These studies have provided insight into novel targets to inhibit in 
combination with ATR inhibitors as a treatment regimen for NSCLC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 
		
AUTOBIOGRAPHICAL STATEMENT 
 
EDUCATION 
Wayne State University                                                                2011-2017 
Doctor of Philosophy: Cancer Biology 
Michigan State University                              2007-2011 
Bachelor of Science: Biology  
 
GRANTS 
University Graduate Research Fellowship- Wayne State University                               2011-2012 
T-32 Training Grant- National Institute of Health (NIH)                                                 2013-2014 
DeRoy Fellowship- Wayne State University                                                                    2014-2015 
Rumble Fellowship- Wayne State University                                                                  2015-2016 
 
PUBLICATIONS 
 
Najor N.A., Weatherford L, Brush GS. Prevention of DNA rereplication through a meiotic 
recombination checkpoint response. G3 (Bethesda). 6(12):3869-3881. 2016. 
 
 
 
 
